Longevity & Anti-Aging

Also known as: Sirolimus, Rapamune, RAPA, AY-22989, WY-090217, NSC-226080, 23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine

Rapamycin is a macrocyclic lactone antibiotic discovered in 1972 in soil samples from Rapa Nui (Easter Island) by a bacteriology survey team investigating indigenous Streptomyces species. Named after its place of discovery, rapamycin was initially developed as an antifungal agent before its immunosuppressive properties were recognized and the molecule was repositioned in the 1980s as a transplant rejection prophylaxis. It received FDA approval in 1999 as sirolimus (trade name Rapamune) for prevention of renal transplant rejection, and has since been approved for additional indications including tuberous sclerosis complex (TSC), lymphangioleiomyomatosis (LAM), drug-eluting coronary stent coating, and (as analogs everolimus and temsirolimus) multiple oncology indications. What makes rapamycin the most-discussed molecule in modern longevity medicine is not its approved indications but its position as the first pharmacological agent demonstrated to consistently extend maximum lifespan in mice across multiple genetic backgrounds, sexes, dosing schedules, and starting ages — a finding from the NIA Interventions Testing Program (ITP) that has been replicated and extended in hundreds of subsequent studies and has positioned rapamycin as the leading candidate for translation into human healthspan and lifespan medicine. Structurally, rapamycin is a complex 31-membered macrolide ring containing an unusual tricarbonyl region that is central to its biological activity. The molecule is poorly water-soluble (logP ~6), highly protein-bound in plasma, and shows complex pharmacokinetics with multiple active metabolites. Its molecular mechanism was elucidated through the 1980s-1990s: rapamycin binds the intracellular protein FK506-binding protein 12 (FKBP12), and the resulting complex binds and inhibits the mechanistic target of rapamycin (mTOR), a serine-threonine kinase that sits at the center of cellular growth, protein synthesis, and autophagy regulation. mTOR exists in two distinct complexes — mTORC1 (with Raptor as a defining component) and mTORC2 (with Rictor) — and acute rapamycin treatment selectively inhibits mTORC1 while leaving mTORC2 largely intact. Chronic rapamycin treatment, however, progressively inhibits mTORC2 as well, which is thought to explain much of the metabolic side-effect profile seen in transplant patients on continuous daily dosing (hyperlipidemia, glucose intolerance, new-onset diabetes). This mTORC1-vs-mTORC2 dosing-schedule distinction is the rationale for the weekly pulsed dosing protocols used in the longevity community, which aim to inhibit mTORC1 intermittently while minimizing mTORC2 impact. The longevity case for rapamycin rests on several converging evidence streams. First, the NIA Interventions Testing Program study by Harrison et al. 2009 (PMID 19587680) demonstrated that rapamycin added to mouse chow extended median and maximum lifespan in genetically heterogeneous mice started on treatment at 600 days of age (approximately equivalent to 60 human years) — the first pharmacological agent to extend lifespan in mice when started in mid-to-late life. Subsequent ITP publications have confirmed and extended this finding across multiple dosing regimens (daily, intermittent, varying doses), across both sexes (with larger effect in females initially but demonstrated in males at higher doses), and across multiple genetic backgrounds. Second, studies in other model organisms (yeast, C. elegans, Drosophila) demonstrated that mTOR inhibition extends lifespan across the tree of life, placing mTOR at the center of an evolutionarily conserved aging pathway. Third, studies in non-human primates (marmosets, published by Tardif and colleagues) have shown safety of long-term rapamycin administration with metabolic biomarker signals consistent with caloric restriction mimicry. Fourth, human trials by Mannick and colleagues — originally with the rapamycin analog everolimus and later with rapamycin itself and the analog RTB101 — demonstrated that mTOR inhibition in elderly humans improves immune response to influenza vaccination and reduces incidence of respiratory infections (PMID 25540326, PMID 29720494), providing human functional evidence that mTOR-inhibition benefits extend beyond mouse longevity signals. Fifth, the PEARL trial (Participatory Evaluation of Aging with Rapamycin for Longevity) conducted by AgelessRx is the first purpose-designed human longevity RCT of rapamycin, with initial results published in 2024 showing improvements in body composition and safety findings consistent with low-dose rapamycin use. Notwithstanding this substantial evidence base, the honest framing is that rapamycin's case in human longevity remains unproven in the rigorous sense. Mouse lifespan extension does not automatically translate to humans — dozens of interventions have worked in mice without translating (growth hormone receptor knockouts, specific antioxidant regimens, metformin in healthy mice). The human trials to date (Mannick immune response, Kraig pilot, PEARL) provide safety and biomarker signals rather than lifespan or healthspan endpoints that would require decades to establish. The longevity-community enthusiasm for rapamycin — driven by Peter Attia's medicine practice, Mikhail Blagosklonny's hyperfunction theory of aging, Matt Kaeberlein's Dog Aging Project, and a growing network of longevity-focused physicians prescribing rapamycin off-label — is based on a reasonable extrapolation from the most-consistent pharmacological lifespan-extension data in gerontology, but it is extrapolation nonetheless. The drug is real, the mouse data are real, the mechanism is real, and the human safety is reasonable at low doses — but the claim that weekly 5-8 mg rapamycin meaningfully extends human healthspan is still hypothesis, not proven fact. Regulatory and access status in the United States: rapamycin (sirolimus, Rapamune) is a prescription drug approved for specific indications; off-label prescription for longevity purposes is legal but not supported by any regulatory approval or standard-of-care guideline. Longevity-focused medical practices (notably AgelessRx, Private Medical, and individual concierge longevity physicians) prescribe rapamycin off-label on the basis of informed-consent shared decision-making. The cost of low-dose pulsed rapamycin is modest ($50-200/month depending on pharmacy and insurance status). Generic sirolimus is available at compounding pharmacies and retail pharmacies. Self-sourcing from research-chemical markets or international pharmacies is inadvisable given the need for pharmaceutical-grade product and appropriate medical monitoring. This entry covers rapamycin's discovery and development history, the mTORC1/mTORC2 mechanism and the dose-schedule rationale, the detailed ITP mouse lifespan data and its translational limits, the approved clinical indications (transplant, TSC, LAM, cancer), the human longevity evidence (Mannick, Kraig, PEARL), the Blagosklonny hyperfunction theory context, practical dosing protocols (Attia-style weekly 5-8 mg, biweekly variants, pre/post-procedure considerations), the characteristic side-effect profile (stomatitis, hyperlipidemia, glucose dysregulation, thrombocytopenia), drug-drug interactions (particularly grapefruit and strong CYP3A4 modulators), monitoring requirements (CBC, lipids, glucose, liver function, trough levels in some contexts), and the honest epistemic framing that balances real mechanistic evidence against the unresolved human translation question. It is offered as information about a prescription medication; clinical use of rapamycin requires a prescribing physician and appropriate monitoring.

Also known as: Glucophage, Glumetza, Riomet, Fortamet, Diabex, Diaformin, 1,1-Dimethylbiguanide, Metformin HCl, N,N-Dimethylbiguanide

Metformin is a biguanide-class oral antihyperglycemic medication that has been in continuous clinical use since 1957 (in France under the brand name Glucophage) and is now the most-prescribed diabetes medication worldwide with over 150 million prescriptions annually. Structurally 1,1-dimethylbiguanide, metformin derives from galegine, the bioactive guanidine alkaloid in Galega officinalis (goat's rue / French lilac / Italian fitch), a plant used in European folk medicine since the middle ages for what medieval physicians described as "sweet urine" — a clinical description consistent with diabetes mellitus. Modern biguanide development began in the 1920s with phenformin and buformin, both of which were withdrawn from most Western markets in the 1970s due to unacceptable rates of lactic acidosis. Metformin emerged as the durable biguanide: approved in the UK in 1958, launched in the US in 1995 (unusually late compared to European and Asian markets due to historical FDA concerns about biguanide safety), and now available in immediate-release and extended-release generic formulations at negligible cost. For type 2 diabetes mellitus (T2DM), metformin is the universally recommended first-line oral therapy based on decades of evidence for glycemic control, modest weight neutrality or weight loss, favorable cardiovascular profile, low hypoglycemia risk (because metformin does not stimulate insulin release), and extremely low cost (generic metformin is typically $4-8/month in the US). The landmark UKPDS (United Kingdom Prospective Diabetes Study) 34 substudy published in 1998 established that metformin reduced all-cause mortality by 36% and myocardial infarction by 39% in overweight T2DM patients versus conventional diet-based therapy — a cardiovascular benefit that became a central rationale for its first-line status. Beyond T2DM, metformin has approved or evidence-supported uses for polycystic ovary syndrome (PCOS) for menstrual regularity, fertility, and weight management; prediabetes and diabetes prevention (the Diabetes Prevention Program, or DPP, demonstrated 31% reduction in progression to diabetes with metformin versus placebo in high-risk individuals); gestational diabetes management; obesity in specific contexts; and increasingly as an adjunct for cancer prevention and treatment based on a large observational evidence base suggesting reduced cancer incidence in metformin-treated T2DM populations. The contemporary interest in metformin as a "longevity drug" derives from several converging evidence streams: (1) the Bannister et al. 2014 observational finding (PMID 25041462) that metformin-treated T2DM patients had LONGER survival than matched non-diabetic controls, a counterintuitive result that raised the hypothesis that metformin could extend healthspan beyond its glycemic effects; (2) preclinical evidence from Anisimov, Martin-Montalvo, and others demonstrating metformin-induced lifespan extension in multiple rodent models (PMID 18992054, 23900178) with effect sizes comparable to or exceeding caloric restriction; (3) the TAME (Targeting Aging with Metformin) clinical trial proposed by Nir Barzilai and colleagues at Albert Einstein College of Medicine (PMID 27304512 conceptual framework), designed as a large multicenter placebo-controlled RCT of metformin in non-diabetic older adults with age-related disease as the primary endpoint; (4) a growing body of observational evidence linking metformin use to reduced incidence of cancer, cardiovascular disease, dementia, and frailty in aged populations; and (5) the favorable safety profile that makes large-scale long-term use feasible. The longevity framework for metformin is not without controversy. Konopka et al. 2019 (PMID 31557590) reported that metformin blunted improvements in insulin sensitivity and aerobic capacity from exercise training in older adults — suggesting that the "pick two: metformin or exercise" tradeoff may be real. The MASTERS trial (Walton 2019, PMID 31402259) similarly showed metformin attenuating muscle hypertrophy gains from resistance training. These findings have produced a reasoned cautious skepticism among aging researchers: metformin may be a valuable drug for diabetic and prediabetic populations but potentially counterproductive for healthy athletic individuals pursuing fitness-based longevity strategies. This entry covers metformin's established pharmacology and T2DM evidence base; the AMPK-complex I-mitochondrial mechanism and the recently-identified GDF15 mediator pathway; the clinical evidence for off-label longevity, cancer prevention, and cardioprotective uses; the Konopka/MASTERS exercise-attenuation findings; the TAME trial framework and the regulatory challenge of approving a drug for aging as a condition; the serious-but-rare lactic acidosis risk and the common vitamin B12 depletion with chronic use; appropriate integration into complete healthspan protocols including exercise, caloric restriction, and other candidate geroprotective interventions; and the practical considerations (IR vs XR formulations, dosing, monitoring) for both diabetic and off-label longevity use.

Also known as: Fisetin, 3,3',4',7-Tetrahydroxyflavone, 2-(3,4-Dihydroxyphenyl)-3,7-dihydroxy-4H-chromen-4-one, Fisetin aglycone, Fustin reduced, Natural Yellow 8, Strawberry flavonoid, Novusetin, Fisetin phytosome, Fisetol

Fisetin is a polyhydroxy flavonoid (3,3',4',7-tetrahydroxyflavone) that has emerged as one of the most extensively studied natural senolytic compounds and a candidate therapy for age-related disease. Structurally it is a flavonol closely related to quercetin but with one fewer hydroxyl group — quercetin is 3,3',4',5,7-pentahydroxyflavone; fisetin is 3,3',4',7-tetrahydroxyflavone, lacking the 5-hydroxyl group. This single structural difference substantially alters fisetin's physicochemical and pharmacokinetic properties compared to quercetin: fisetin has better lipophilicity, superior blood-brain barrier penetration, higher oral bioavailability in its aglycone form, and a distinct profile of senolytic selectivity in cellular screening studies. Fisetin occurs in a narrow range of dietary sources with strawberries as by far the richest: fresh strawberries contain 160 mcg/g (approximately 20-25 mg per cup of strawberries). Other dietary sources are substantially lower: apples (27 mcg/g), persimmons (11 mcg/g), lotus root (6 mcg/g), onions (5 mcg/g), grapes (4 mcg/g), kiwi (2 mcg/g), cucumbers (1 mcg/g), and tomatoes, peaches, and other fruits in trace amounts. The acacia tree (Acacia greggii and Acacia berlandieri) produces fisetin as a heartwood constituent, and many commercial fisetin supplements are extracted from Rhus succedanea (Japanese wax tree) or similar botanical sources rather than from strawberries directly. Typical Western diets provide under 1 mg of fisetin daily, making food-based supplementation insufficient for the doses associated with senolytic effects (100+ mg daily of bioavailability-enhanced fisetin or higher pulse-dose protocols). The modern interest in fisetin as a therapeutic agent derives primarily from a 2018 study by Yousefzadeh and colleagues published in EBioMedicine (PMID 30213834) titled "Fisetin is a senotherapeutic that extends health and lifespan." The study screened 10 natural flavonoids for senolytic activity in cultured murine fibroblasts and found that fisetin was the most potent, producing 25-50% reduction of senescent cells at 5 micromolar concentration compared to less than 10% reduction for most other tested flavonoids. The study then administered fisetin 100 mg/kg or 500 mg/kg via oral gavage to aged (22-24 month old) C57BL/6 mice for 5 consecutive days every two weeks, and reported reductions in senescence markers across multiple tissues including adipose, kidney, liver, and spleen. Physical function improved in aged mice receiving fisetin, and median lifespan was extended by approximately 10% from the start of treatment at 85 weeks. These findings — extending lifespan and healthspan in aged mice with a naturally-occurring orally-bioavailable food-derived compound — generated immediate interest in human translation. Subsequent research has expanded fisetin's profile. Kim 2016 (PMID 26865036) reviewed fisetin's neuroprotective effects in Alzheimer's disease models. Maher 2015 (PMID 25757681) showed fisetin attenuated Alzheimer's-related deficits in APP/PS1 mice. Wang 2019 reviewed fisetin in cancer applications with in vitro evidence for multiple tumor types. Mahmoudi 2018 reviewed fisetin in osteoarthritis models. Multiple in vitro cellular screening studies have consistently identified fisetin among the most selective senolytic natural compounds, with enhanced selectivity for senescent over non-senescent cells compared to other tested flavonoids. Clinical translation has been deliberate but slow. As of 2026, multiple Phase 2 trials are underway including the AFFIRM-LITE trial at Mayo Clinic (NCT03675724) testing fisetin 20 mg/kg for 2 consecutive days monthly in frail elderly women for functional and biomarker outcomes; the trial dosing protocol has become the reference standard for human senolytic use of fisetin. Other trials are recruiting in osteoarthritis, post-COVID fatigue syndromes, diabetic kidney disease, and mild cognitive impairment. Hickson and colleagues at Mayo have published pilot experience with intermittent senolytic dosing using fisetin and D+Q combinations. Pharmacokinetically fisetin has a plasma half-life of approximately 3-5 hours for free aglycone and up to 9 hours for glucuronide conjugates. Plasma protein binding is high (>95%). Oral bioavailability of standard aglycone is approximately 40-70% in some studies — substantially higher than quercetin aglycone's 2-10%. Bioavailability-enhanced formulations including fisetin phytosome (lecithin complex) further increase plasma levels 3-5-fold compared to aglycone. Tissue distribution is broad with relatively high concentrations in brain, liver, kidney, and adipose tissue. Blood-brain barrier penetration is substantially better than quercetin, making fisetin particularly attractive for central nervous system applications. Commercial fisetin supplementation products typically source fisetin from extraction of Rhus succedanea (Japanese wax tree) or Acacia greggii heartwood, with purification to 90-98% fisetin content. Novusetin (HealthStar) is a standardized 98% fisetin ingredient used in multiple commercial products. Fisetin phytosome formulations using sunflower lecithin provide improved bioavailability. Synthetic fisetin is also available and is molecularly identical to natural-source material. Typical supplementation doses range from 100 mg daily (low maintenance) to 1500 mg per dose (senolytic pulse dosing in an average adult). The senolytic protocol following AFFIRM-LITE dosing corresponds to approximately 20 mg/kg for 2 consecutive days taken once monthly — for a 70-kg person, that is 1400 mg per day for 2 days per month. This intermittent pulse dosing mimics the mouse protocol from Yousefzadeh 2018 scaled by body weight. For bodyhackguide.co users, fisetin occupies a specific and growing place in the senolytic and longevity supplementation landscape. It pairs naturally with quercetin (closely related flavonoid, often co-used during senolytic days), dasatinib (prescription senolytic partner in D+Q protocol), curcumin (complementary polyphenol anti-inflammatory), resveratrol and pterostilbene (stilbene polyphenols with overlapping longevity mechanisms), spermidine (autophagy inducer), rapamycin (mTOR inhibitor, longevity gold standard), NMN and nicotinamide-riboside (NAD precursors), omega-3, vitamin-d3, and magnesium for complete longevity protocols. The canonical recommendation for senolytic use is the AFFIRM-LITE-style protocol of 20 mg/kg for 2 consecutive days monthly (approximately 1400-1600 mg for an adult) using a bioavailability-enhanced formulation, with continuous low-dose maintenance (100-200 mg daily) as an optional complement.

Also known as: Sprycel (brand name), BMS-354825, N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide, BCR-ABL inhibitor, Src family kinase inhibitor, D (in D+Q senolytic combination)

Dasatinib (SPRYCEL) is a second-generation oral tyrosine kinase inhibitor (TKI) with FDA approvals for chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). It is also, critically for longevity medicine, the "D" component of the landmark D+Q (dasatinib + quercetin) senolytic drug combination first reported by Zhu, Tchkonia, and Kirkland in 2015 (PMID 25754370) — the first demonstrated pharmacologic strategy to selectively kill senescent cells ("zombie cells") while sparing healthy cells. Senescent cells accumulate with age and disease, secrete pro-inflammatory and tissue-damaging SASP (senescence-associated secretory phenotype) factors, and contribute to age-related dysfunction across multiple organs. The D+Q combination and subsequent senolytic discoveries have opened an entire new therapeutic category of geroscience interventions with two landmark first-in-human pilot trials completed (Justice 2019 PMID 30616998 in idiopathic pulmonary fibrosis; Hickson 2019 PMID 31542391 in diabetic kidney disease), numerous additional senolytic trials underway, and substantial preclinical evidence across aging, Alzheimer disease, osteoarthritis, atherosclerosis, obesity-associated metabolic dysfunction, frailty, and multiple other age-related conditions. Dasatinib's chemical structure is a pyrimidinyl-aminothiazole-carboxamide that functions as an ATP-competitive inhibitor of multiple tyrosine kinases, with particular potency against BCR-ABL, the SRC family kinases (SRC, LCK, YES, FYN), c-KIT, PDGFR-α/β, and ephrin receptors. Originally developed by Bristol-Myers Squibb as a second-generation BCR-ABL inhibitor for patients with imatinib-resistant or -intolerant CML, dasatinib is 325-fold more potent than imatinib against wild-type BCR-ABL and retains activity against most imatinib-resistant mutations except T315I (which requires ponatinib). FDA-approved for: CML in all phases (chronic, accelerated, blast); Ph+ ALL in adults and pediatrics; use in adult patients with chronic phase CML with resistance or intolerance to prior therapy (second-line) or newly-diagnosed chronic phase CML (first-line); pediatric CML in chronic phase. The compound is marketed by Bristol-Myers Squibb (BMS) as SPRYCEL with substantial global presence since 2006. Dosing for oncologic indications ranges from 100 mg once daily (standard for chronic-phase CML) to 140 mg daily or 70 mg BID (for advanced CML or Ph+ ALL), taken continuously until disease progression or unacceptable toxicity. This pharmacologic profile — daily oral administration with continuous dosing at 100-140 mg — is the high-exposure scenario from which extensive clinical safety data and drug interaction knowledge have been accumulated. The senolytic paradigm is fundamentally different. For senolytic applications, dasatinib is used in INTERMITTENT PULSED DOSING — typically 100 mg once daily for 2-3 consecutive days, followed by a long drug-free interval (weeks to months). This dosing strategy reflects the biology: senolytic effects occur through a "hit-and-run" mechanism where the drug kills vulnerable senescent cells within hours to days, and continuous daily exposure is both unnecessary and likely counterproductive. The Justice 2019 trial used dasatinib 100 mg + quercetin 1000 mg on 3 consecutive days, with follow-up at 1 week and 1 month, finding meaningful functional improvements in IPF patients. The Hickson 2019 trial used dasatinib 100 mg + quercetin 1000 mg on 3 consecutive days, with measured senescent cell reduction in adipose tissue at 11 days post-treatment. Subsequent trials are exploring varied intermittent dosing schedules (e.g., monthly or quarterly pulsed dosing). This intermittent paradigm dramatically reduces cumulative exposure compared to chronic oncologic dosing — a patient receiving 100 mg × 2 days monthly gets ~2400 mg annually, compared to ~36,500 mg annually for a chronic CML patient — with correspondingly reduced but not eliminated side effect risk. Dasatinib's side effect profile is substantial and requires careful consideration even for intermittent senolytic use. Myelosuppression (thrombocytopenia, neutropenia, anemia) is common and dose-related, with thrombocytopenia being particularly notable — dasatinib potently inhibits SRC-family kinases in platelets, producing both quantitative reduction in platelet number and qualitative impairment of platelet function (increased bleeding risk independent of count). Pleural effusion is a well-described class effect (more common with dasatinib than other BCR-ABL TKIs), occurring in 10-30% of chronic daily-dosed patients and requiring monitoring. QTc prolongation and rare cardiac arrhythmias have been reported. Pulmonary arterial hypertension (rare but serious) can occur with prolonged exposure. GI side effects (diarrhea, nausea) are common. Multiple reports exist of dasatinib-induced colitis and GI bleeding. Drug interactions are extensive (CYP3A4 substrate; strong CYP3A4 inhibitors substantially increase dasatinib exposure; proton pump inhibitors dramatically reduce dasatinib absorption by raising gastric pH). For senolytic applications, intermittent pulsed dosing reduces but does not eliminate these concerns — patients have experienced adverse events at senolytic dosing schedules, and the intermittent paradigm is not risk-free. Dasatinib is a prescription medication; its use for any indication requires physician prescription, monitoring, and supervision. For longevity/senolytic use specifically, this requires partnership with a physician familiar with geroscience — typically a functional medicine, integrative medicine, or specifically-trained longevity physician. Self-experimentation with research-chemical-sourced dasatinib is both illegal (in most jurisdictions) and medically inappropriate given the substantial side effect profile and need for baseline and monitoring labs (CBC, LFTs, ECG, periodic echo for pulmonary pressure assessment). This entry covers dasatinib's pharmacology as a tyrosine kinase inhibitor; its established oncology indications; the senolytic mechanism and D+Q rationale; the clinical evidence base for senolytic applications including Justice 2019 IPF trial and Hickson 2019 DKD trial; the intermittent dosing paradigm for senolytic use; the substantial safety and interaction considerations; integration with fisetin, quercetin, rapamycin, and other geroscience interventions; and the essential role of physician partnership in any senolytic use.

Also known as: FOXO4

FOXO4-DRI is a synthetic 34-amino-acid D-retro-inverso peptide designed to disrupt the interaction between the FOXO4 transcription factor and p53, with the specific goal of inducing apoptosis selectively in senescent cells. The compound was developed by the laboratory of Peter de Keizer at Erasmus Medical Center and reported in a landmark 2017 Cell paper that demonstrated FOXO4-DRI administration to aged mice produced measurable reductions in senescent cell burden, restored renal function, improved fur density and grooming behavior, and extended several markers of organismal health without apparent toxicity at effective doses (Baar et al., 2017). The publication was widely covered in mainstream science media and became one of the most cited demonstrations of targeted senolytic therapy as a plausible anti-aging strategy. The underlying biology is that cellular senescence — a state of permanent cell-cycle arrest induced by replicative exhaustion, DNA damage, oncogenic signaling, or mitochondrial dysfunction — accumulates with age in multiple tissues and contributes to tissue dysfunction through the senescence-associated secretory phenotype (SASP), a paracrine signature of pro-inflammatory cytokines, matrix-degrading proteases, and growth factors that damages neighboring cells and impairs tissue homeostasis. Selectively eliminating senescent cells while sparing non-senescent neighbors is the core concept of senolytic therapy, and multiple classes of molecules have been developed to pursue this goal: the dasatinib-quercetin combination, ABT-263 (navitoclax), fisetin, the p53 activator UBX0101 (now largely abandoned), and FOXO4-DRI represent distinct mechanistic strategies within the senolytic space (Kirkland & Tchkonia, 2020). FOXO4-DRI specifically targets a vulnerability identified in senescent cells: they depend on sequestration of p53 away from the mitochondrial outer membrane to avoid apoptosis, and this sequestration is maintained by a physical interaction between FOXO4 and p53 at specific nuclear sites. Disrupting the FOXO4-p53 interaction with FOXO4-DRI releases p53 to translocate to mitochondria, where it triggers the intrinsic apoptosis pathway in senescent cells that have accumulated pro-apoptotic signals but been held alive by the FOXO4-p53 sequestration. Non-senescent cells, which do not have the same accumulated pro-apoptotic signaling, are not killed by FOXO4-DRI administration (Baar et al., 2017; Bourgeois & Madl, 2018). The peptide is chemically distinctive because it is built as a D-retro-inverso (DRI) isomer, meaning it uses D-amino acids in reverse sequence compared to the parent L-peptide. This structural trick produces a molecule with roughly the same three-dimensional shape as the original but with complete protease resistance, because human proteases cannot recognize D-amino acid bonds. DRI peptides are used throughout the peptide-drug field when the natural L-peptide is too short-lived in vivo to be useful. The FOXO4-DRI sequence specifically is derived from the FOXO4 region that contacts p53, and the D-retro-inverso construction maintains the binding affinity while extending plasma and tissue half-life to useful ranges. The practical reality of FOXO4-DRI in April 2026 is that it remains an investigational research peptide with no approved human use, no clinical trials registered or published, and no pharmaceutical-grade manufacturing. Research-peptide vendors sell what they claim is FOXO4-DRI for "research purposes only," and a biohacker community has accumulated several years of self-experimentation experience with the compound. This entry covers the mechanism in detail, the original Baar et al. 2017 study and what it actually showed, subsequent work that has attempted to reproduce and extend the findings, the theoretical and practical concerns with self-administration, why the compound has not progressed to human trials despite its prominence, and what realistic thinking about FOXO4-DRI looks like in the context of the broader senolytic field.

Also known as: Spermidine, N-(3-Aminopropyl)butane-1,4-diamine, Aminopropyl-putrescine, Polyamine, Wheat germ spermidine, spermidineLIFE, Primeadine, Longevity polyamine, Sperm polyamine (historical), Natural polyamine

Spermidine is a naturally-occurring polyamine essential for cellular growth, division, and differentiation in all living organisms. It was first isolated from semen (hence the name) in the 17th century by Anton van Leeuwenhoek, but is synthesized endogenously by all mammalian cells and is also present in substantial concentrations in many dietary sources. Over the past decade, spermidine has emerged as one of the most promising longevity-associated molecules, with compelling evidence for extending lifespan across multiple model organisms and strong preclinical data for cardiovascular protection, neuroprotection, immune enhancement, and metabolic benefits. The molecule has transitioned from obscurity to major interest following pioneering work by Frank Madeo and colleagues culminating in a 2018 Nature Medicine publication demonstrating associations between dietary spermidine intake and reduced cardiovascular mortality in humans. Chemically, spermidine is a linear triamine (N-(3-aminopropyl)butane-1,4-diamine) with three amine groups that are positively charged at physiological pH. This positive charge enables spermidine to bind to negatively-charged cellular components including DNA, RNA, nucleotides, ATP, phospholipids, and many proteins. The electrostatic interactions stabilize nucleic acid structures, facilitate transcription and translation, influence membrane organization, and participate in numerous enzymatic processes. Spermidine is one of three major polyamines in mammalian cells (alongside putrescine and spermine), with spermidine typically the most abundant. Intracellular concentrations range from micromolar to millimolar depending on cell type. Endogenous spermidine synthesis occurs from putrescine via spermidine synthase, requiring S-adenosylmethionine (SAM) as the aminopropyl donor. Cellular spermidine levels are tightly regulated through coordinated synthesis, uptake from extracellular sources, efflux via polyamine transporters, and catabolism. Polyamine levels decline with aging in most tissues, including heart, brain, liver, and blood cells, contributing to age-related cellular dysfunction. Restoring polyamine levels through dietary or supplemental spermidine is the basis for its proposed geroprotective effects. Dietary spermidine is abundant in many foods with wheat germ containing the highest concentrations (approximately 240 mg/kg). Other rich sources include soybeans (soybeans and soybean products at approximately 100-200 mg/kg), aged cheese, mushrooms, peas, mango, broccoli, cauliflower, whole grains, and fermented foods. Typical Western dietary intake provides 10-25 mg spermidine daily, while Mediterranean-style diets with emphasis on legumes, whole grains, and vegetables provide higher amounts (25-50 mg daily). Japanese populations consuming natto and other fermented soy foods often achieve intakes of 40-80+ mg daily. The modern scientific interest in spermidine derives from a series of landmark studies. Eisenberg and colleagues (2009, PMID 19858987) demonstrated that spermidine extends lifespan across yeast, flies, worms, and mouse models through induction of autophagy. This was one of the most reproducible lifespan-extension findings across model organisms. Eisenberg 2016 (PMID 27841876) showed oral spermidine extended mouse lifespan and reduced cardiovascular aging markers. The landmark Kiechl 2018 Bruneck Study publication in Nature Medicine (PMID 30150389) analyzed 20-year follow-up of the Bruneck cohort in Italy and found higher dietary spermidine intake was associated with reduced overall mortality, cardiovascular mortality, and cancer mortality. Follow-up cohort studies from Austria, Sweden, and Japan have replicated the general association between higher dietary spermidine and reduced mortality risk. Commercial spermidine supplementation typically uses wheat germ extract standardized to spermidine content. SpermidineLIFE (Longevity Labs) became one of the first major commercial brands in 2017-2018 offering standardized wheat germ extract providing 1-5 mg spermidine per serving. Primeadine (Oxford Healthspan) is a competing brand using similar wheat germ-based formulation. Pure synthetic spermidine is available as a research chemical but is generally not commercially sold for human supplementation due to regulatory and standardization concerns. Typical supplementation doses range from 1-2 mg daily (foundation dose, matching upper range of dietary intake) to 10+ mg daily (therapeutic doses used in clinical trials). Pharmacokinetically dietary and supplemental spermidine is absorbed efficiently from the intestinal lumen, with polyamine transporters mediating uptake into enterocytes and subsequent distribution to tissues. Plasma half-life is short (minutes to hours for free spermidine) due to rapid cellular uptake. However, tissue accumulation from continued dietary intake produces sustained effects on cellular polyamine pools. Measurement of intracellular spermidine levels is technically complex; most clinical studies rely on dietary intake estimation or plasma polyamine profiling. The thematic positioning of spermidine in contemporary longevity supplementation is as a foundational autophagy-inducing geroprotector alongside NAD+ precursors, polyphenols, and sirtuin activators. Its unique mechanism (polyamine-mediated autophagy induction and protein translation quality control) complements rather than duplicates mechanisms of NR/NMN (sirtuin substrate), pterostilbene (sirtuin activator), or fisetin (senolytic). Multiple longevity-focused commercial stacks now include spermidine alongside these other compounds. Its safety profile at dietary and typical supplemental doses is excellent, with generations of dietary safety data from diverse populations.

Also known as: Pterostilbene, trans-3,5-Dimethoxy-4'-hydroxystilbene, (E)-1-(3,5-Dimethoxyphenyl)-2-(4-hydroxyphenyl)ethylene, 3',5'-Dimethoxyresveratrol, trans-Pterostilbene, pTeroPure, Pterostilbene phytosome, Dimethylresveratrol, Blueberry stilbene, Pterocarpus marsupium stilbene

Pterostilbene is a naturally-occurring stilbene polyphenol (trans-3,5-dimethoxy-4'-hydroxystilbene) that is structurally and functionally related to resveratrol but has substantially superior pharmacokinetic properties. Chemically, pterostilbene differs from resveratrol by the replacement of two hydroxyl groups at the 3 and 5 positions on one of the phenyl rings with methoxy groups. This seemingly small structural difference produces dramatic pharmacokinetic consequences: pterostilbene has much higher oral bioavailability (approximately 80% in rodent studies versus under 5% for resveratrol), a substantially longer plasma half-life (105 minutes versus 14 minutes for resveratrol), much greater metabolic stability, enhanced tissue penetration, and different target affinities. Pterostilbene is often described as a "bioavailable resveratrol" in consumer materials, which captures the essential clinical reality that pterostilbene at 50-150 mg reaches tissue concentrations comparable to resveratrol at 500-1500 mg or higher. Pterostilbene was first isolated in 1956 from Pterocarpus marsupium (Indian kino tree), a medicinal plant used in traditional Indian medicine for diabetes and metabolic disorders. The compound is also produced naturally by several plants as a phytoalexin — a defensive compound produced in response to fungal infection or stress. Dietary sources of pterostilbene are dominated by blueberries, which contain 99-520 ng per gram of fresh fruit (approximately 15-100 mcg per cup of blueberries) depending on cultivar. Other notable sources include grape leaves (trace amounts), almonds (trace amounts), and some berries. The blueberry content is sufficient that regular dietary blueberry consumption delivers measurable pterostilbene exposure, though doses corresponding to therapeutic supplementation levels (50-250 mg daily) exceed realistic dietary attainability. Modern scientific interest in pterostilbene derives from three converging lines of research. First, beginning in the late 1990s and early 2000s, researchers studying resveratrol's pharmacokinetic limitations identified pterostilbene as a structural analog with dramatically better bioavailability — offering the possibility of achieving meaningful in vivo drug levels at clinically practical oral doses. Second, mechanistic research established that pterostilbene activates many of the same longevity-associated pathways as resveratrol, including SIRT1, AMPK, and Nrf2, while also having distinct activities including PPAR-alpha modulation and lipid metabolism effects. Third, a series of human clinical trials conducted beginning in 2012 established pterostilbene's human safety and documented effects on blood pressure, lipid profiles, oxidative stress markers, and cognitive function. Key clinical work includes Riche 2013 (PMID 23615358) conducted at the University of Mississippi: a randomized controlled trial of 80 adults with hypertension and dyslipidemia receiving pterostilbene 125 mg twice daily or placebo for 6-8 weeks showed pterostilbene produced small but measurable reductions in systolic blood pressure (approximately 7 mmHg), with modest changes in lipid profile. Riche 2014 (PMID 25048360) reported longer-term safety data and noted pterostilbene at high doses (250 mg twice daily) produced a modest increase in LDL cholesterol in a subset of participants, prompting dose refinements in subsequent trials. McCormack 2012 (PMID 22082792) provided human pharmacokinetic data confirming pterostilbene is well-absorbed orally with bioavailability in the 70-80% range in human volunteers. Rimando 2002 (PMID 12010004) quantified pterostilbene content across blueberry cultivars, establishing blueberries as the dominant dietary source. Tani 2014 and related studies have extended the pharmacokinetic and mechanistic understanding. Pterostilbene has been commercialized primarily through the pTeroPure ingredient developed by ChromaDex, which provides >99% pure synthetic pterostilbene under a standardized manufacturing and testing regime. Commercial finished products containing pTeroPure include Elysium Health's Basis (pterostilbene 50 mg + nicotinamide riboside 250 mg — a combination supplement positioned as a foundational longevity formula), multiple ChromaDex-partner brands, and independently branded pterostilbene products from manufacturers who license the pTeroPure ingredient. Pterostilbene phytosome formulations (lecithin-complexed) provide further bioavailability enhancement for sensitive applications. Typical supplementation doses range from 50 mg daily (low maintenance, often paired with 250-500 mg NR or NMN) to 150-250 mg daily (therapeutic doses used in the Riche hypertension trials). Doses above 250 mg daily are generally not recommended without specific clinical rationale due to the LDL elevation signal observed at higher doses. The thematic positioning of pterostilbene in longevity supplementation is as the bioavailable stilbene complement to NAD+ precursors: the Basis formulation pairing pterostilbene with nicotinamide riboside reflects a theoretical model where NR provides substrate for sirtuin enzymes and pterostilbene activates those enzymes, producing a combined effect exceeding either alone. The underlying mechanistic logic has strong preclinical support but limited randomized clinical trial evidence for combined product effects. Nevertheless, pterostilbene has become established as a well-tolerated, bioavailable, orally-effective SIRT1/AMPK activator suitable for long-term daily supplementation in adults pursuing longevity-oriented health goals.

Also known as: Mitopure, UA, Ellagitannin metabolite, 3,8-dihydroxy-6H-dibenzo[b,d]pyran-6-one, Urolithin

Urolithin A (3,8-dihydroxy-6H-dibenzo[b,d]pyran-6-one; trade name Mitopure from Timeline Nutrition, formerly Amazentis) is a gut-microbiome-derived metabolite of dietary ellagitannins — polyphenolic compounds found in pomegranates, walnuts, strawberries, raspberries, and several other berries. Unlike most dietary polyphenols, ellagitannins themselves are poorly absorbed from the intestine; their health-relevant bioactivity depends on conversion by specific gut bacteria (primarily Gordonibacter species, along with some Lactobacillus and Bifidobacterium strains) into a family of smaller metabolites called urolithins, of which urolithin A is the most biologically active. This microbial conversion is not universal — published surveys suggest only 30-40 percent of Western adults harbor the gut bacteria necessary to produce meaningful urolithin A from dietary ellagitannin consumption, with the remaining majority producing mainly urolithin B, urolithin C, or minimal urolithin production at all. The conversion capacity ("metabotype") depends on gut microbiome composition shaped by diet, antibiotic history, age, and unknown factors. Direct urolithin A supplementation bypasses the microbiome-dependent conversion step, providing consistent bioactive exposure regardless of individual metabotype. The scientific story of urolithin A as a longevity-relevant molecule begins with a landmark 2016 paper by Ryu and colleagues at EPFL (École Polytechnique Fédérale de Lausanne) in Switzerland and the biotechnology company Amazentis, published in Nature Medicine (Ryu et al. 2016, PMID 27454312). The authors screened a library of microbial metabolites for mitochondrial activity and identified urolithin A as a potent inducer of mitophagy — the selective autophagic degradation of damaged mitochondria — in both Caenorhabditis elegans and aged mice. Urolithin A extended lifespan in C. elegans, improved muscle function in aged mice, and reduced markers of mitochondrial dysfunction. Mitophagy, the specific form of autophagy that targets mitochondria for degradation, had by then emerged as a central process in mitochondrial quality control: damaged mitochondria that accumulate with age are normally targeted for degradation via PINK1/Parkin and related pathways, but this mitophagy machinery itself declines with age, producing a vicious cycle of mitochondrial damage accumulation. Urolithin A's demonstrated ability to induce mitophagy even in aged systems made it an attractive candidate for clinical translation. Timeline (formerly Amazentis) developed and commercialized urolithin A as Mitopure, with pharmaceutical-grade material supported by human clinical trials demonstrating safety, bioavailability, and biomarker effects on mitochondrial function. Phase 1 (Andreux et al. 2019, PMID 31477902) established safety at doses up to 1,000 mg daily and measured biomarker changes in skeletal muscle. Phase 2 trials (Liu et al. 2022, PMID 36345188 and Singh et al. 2022, PMID 35732821) demonstrated improvements in muscle function and mitochondrial biomarkers in middle-aged and older adults. A series of biomarker and mechanistic studies confirmed induction of mitophagy in human tissues following urolithin A administration. Current commercial products are based on this evidence foundation and include Mitopure capsules and softgels, along with various third-party urolithin A products of variable quality. Unlike many longevity compounds that remain investigational or available only through unregulated suppliers, urolithin A has achieved GRAS (Generally Recognized as Safe) status in the United States for several commercial forms, allowing mainstream supplement distribution. Mechanistically, urolithin A addresses a specific, important, and previously underaddressed aspect of aging: mitochondrial quality control through selective turnover of damaged mitochondria. Aging tissues accumulate dysfunctional mitochondria with reduced respiratory capacity, increased ROS production, damaged membranes, and impaired calcium handling. Removing these damaged organelles is a prerequisite for replacing them with functional ones through mitochondrial biogenesis. If the mitophagy machinery is slow or insufficient, damaged mitochondria accumulate even in the presence of adequate biogenesis signals. Urolithin A accelerates this turnover, functionally "rejuvenating" the mitochondrial population by favoring the retention of healthy organelles and the removal of damaged ones. This mechanism is complementary to and distinct from the effects of other mitochondrial interventions: SS-31 stabilizes mitochondrial membranes to preserve existing mitochondrial function; NMN elevates NAD+ to support mitochondrial biochemistry; CoQ10 provides electron transport chain cofactor; exercise induces both biogenesis and mitophagy. Urolithin A specifically enhances the quality control step that complements these other interventions, and a complete mitochondrial longevity approach often incorporates multiple mechanisms working together. Practical considerations for urolithin A use are favorable relative to most longevity interventions. Oral bioavailability is moderate (published pharmacokinetic data show meaningful plasma and tissue exposure after oral dosing), eliminating the need for injections required by peptides like SS-31 or MOTS-c. Cost is moderate — commercial Mitopure products run $40-80 monthly at standard doses, while generic urolithin A from reputable supplement companies runs $20-40 monthly. Safety profile is excellent, with clinical trials reporting good tolerability and commercial post-market experience showing minimal concerns. Dosing is straightforward (once daily with food), and timing does not require specialized scheduling. These practical advantages make urolithin A one of the more accessible serious mitochondrial interventions available to consumers, appropriate for users ranging from cautious beginners to advanced longevity practitioners. Users should calibrate expectations appropriately. Published clinical trials show real but modest effects on mitochondrial biomarkers and muscle function in middle-aged and older adults, with effect sizes in the range typical for other longevity interventions rather than dramatic transformation. The most relevant applications appear to be age-related muscle function decline (sarcopenia prevention), general mitochondrial health support, and complementary coverage within a broader mitochondrial stack. Urolithin A does not cure age-related decline, does not substitute for exercise (which remains the most potent mitochondrial biogenesis stimulus available), and does not address aspects of aging outside mitochondrial quality control. It is best viewed as one useful tool among several for mitochondrial health, with specific advantages in addressing mitophagy that most other interventions do not cover directly. The microbiome dimension of urolithin A raises interesting questions for users. Some individuals are natural "high converters" who produce urolithin A endogenously from dietary ellagitannins; these individuals may have lower marginal benefit from direct supplementation. Most Western adults are non-converters or low converters who produce little or no urolithin A from pomegranate and walnut consumption; for these individuals, direct supplementation provides access to a bioactive that would otherwise be unavailable from diet. Commercial urinalysis tests can identify urolithin metabotype, though most users skip this step and simply supplement directly based on the reasonable assumption that they are probably not a high converter. Diet continues to matter: even with supplementation, consumption of pomegranate, walnuts, berries, and other ellagitannin sources supports broader polyphenol intake and related health benefits, and the small fraction of users who are high converters produce endogenous urolithin A from these foods. Positioning urolithin A within a longevity strategy: it integrates naturally with exercise (the fundamental mitochondrial intervention), a solid mitochondrial supplement foundation (CoQ10, NMN, creatine, omega-3), and other complementary interventions as budget and goals allow. For many users, urolithin A offers a meaningful quality-of-life and functional-capacity signal with favorable cost, convenience, and safety — making it one of the more defensible additions to a longevity stack compared to higher-cost or higher-risk experimental options.

Also known as: Astaxanthin, Ovoester, 3,3'-dihydroxy-beta,beta-carotene-4,4'-dione, AstaReal, BioAstin, AstaZine, Haematococcus pluvialis extract, Natural astaxanthin, Algal astaxanthin, Haematococcus astaxanthin, Synthetic astaxanthin, (3S,3'S)-astaxanthin, Astaxanthin diester, Astaxanthin monoester, Astaxanthin oleoresin, Salmon pink pigment, E161j, CI 40820

Astaxanthin is a red-orange keto-carotenoid xanthophyll, chemically classified as a 3,3''-dihydroxy-beta,beta-carotene-4,4''-dione. Unlike beta-carotene, astaxanthin does not convert to vitamin A in mammals, which eliminates concerns about vitamin A toxicity at high supplementation doses and removes the competitive absorption issues that plague beta-carotene in retinol-replete individuals. Astaxanthin occurs naturally in the microalga Haematococcus pluvialis (which produces astaxanthin as a stress-response pigment reaching up to 4% of dry weight), in the yeast Xanthophyllomyces dendrorhous, in certain bacteria, and is concentrated up the aquatic food chain into crustaceans (shrimp, krill, lobster), salmon, and flamingo plumage. The salmon pink color in wild Pacific salmon comes predominantly from astaxanthin accumulated from krill; farmed salmon are typically supplemented with synthetic astaxanthin to achieve the expected color. Astaxanthin is one of the most potent naturally occurring antioxidants characterized in biological chemistry, with singlet oxygen quenching rates 6,000 times greater than vitamin C, 550 times greater than vitamin E, and 40 times greater than beta-carotene in standardized assays (Miki 1991). This singular antioxidant efficiency — combined with the molecule's distinctive ability to span the phospholipid bilayer of cell membranes with its polar end groups at each aqueous interface — underlies astaxanthin's broad biological activity across tissues and its position as one of the better-evidenced carotenoid supplements for skin, eye, cardiovascular, and athletic outcomes. The chemistry of astaxanthin differs from most dietary carotenoids in ways that matter for physiology. Carotenoids broadly divide into carotenes (pure hydrocarbons — beta-carotene, alpha-carotene, lycopene) and xanthophylls (oxygenated carotenoids — lutein, zeaxanthin, astaxanthin, canthaxanthin). Astaxanthin is a keto-xanthophyll, carrying two keto (C=O) groups and two hydroxyl (C-OH) groups on the terminal beta-ionone rings. This terminal polar oxygenation gives astaxanthin an amphipathic character — nonpolar in the middle (the 13-conjugated-double-bond polyene chain) and polar at each end — that allows astaxanthin to orient across phospholipid membranes with its polar ends at the aqueous-lipid interfaces. This orientation is unique among common carotenoids and is the structural basis for astaxanthin's exceptional membrane antioxidant activity — the keto-hydroxyl ends can quench both lipid-soluble and water-soluble radicals at the membrane interface. The 13-double-bond conjugated system makes astaxanthin an efficient singlet oxygen quencher (dissipating excitation energy as heat rather than generating reactive species), and the keto groups allow single-electron transfer and adduct formation with reactive species. Astaxanthin occurs as three stereoisomers (3S,3''S; 3R,3''R; and 3R,3''S/meso) at the two hydroxyl carbons. Natural astaxanthin from Haematococcus pluvialis is predominantly (3S,3''S) with 70-100% in the monoester and diester forms (fatty acid esterified at the hydroxyl groups), which confers better stability and controlled-release bioavailability. Synthetic astaxanthin (used extensively in aquaculture feed to pigment farmed salmon) is a racemic mixture approximately 1:2:1 of (3S,3''S):(3R,3''S):(3R,3''R) in free (non-esterified) form. The natural/synthetic distinction matters for supplementation: natural Haematococcus-derived astaxanthin is the form used in virtually all published human supplementation trials and is the form with regulatory clearance in most jurisdictions for human dietary supplements. Synthetic astaxanthin is FDA-approved for aquaculture feed but has more limited human safety evaluation. BodyHackGuide recommends natural Haematococcus-derived astaxanthin for all human supplementation. The adult human body does not naturally contain substantial astaxanthin — humans do not synthesize it and typical Western dietary intake is approximately 1-4 mg/day from salmon, trout, shrimp, and other seafood (substantially lower in non-seafood-consuming populations). Supplementation at 4-12 mg/day places astaxanthin tissue concentrations well above typical dietary levels and allows accumulation in skin, eye (retina and macula), brain, heart, and muscle tissue. Astaxanthin is one of the few carotenoids that readily crosses the blood-brain barrier and the blood-retinal barrier, giving it access to tissues where other carotenoids (beta-carotene, lutein in the macula only via specific transport, zeaxanthin similarly restricted) are excluded or limited. Absorption of astaxanthin is lipid-dependent — the molecule is lipophilic and requires dietary fat for efficient micelle incorporation and subsequent chylomicron-mediated absorption. Fasting absorption is poor; coadministration with a fat-containing meal increases bioavailability 2-4 fold. Natural astaxanthin esters (from Haematococcus) are hydrolyzed by pancreatic lipase and intestinal esterases to free astaxanthin, which is absorbed with lipids into chylomicrons and delivered via lymphatics to systemic circulation. Plasma Cmax is typically reached 6-11 hours after oral administration. Plasma half-life is approximately 52-72 hours — one of the longer half-lives among dietary antioxidants, which allows once-daily dosing to maintain stable plasma concentrations. Distribution favors lipid-rich tissues including adipose tissue, liver, skin, brain, and retina. Excretion is predominantly biliary with fecal elimination; urinary excretion is minimal. The clinical evidence for astaxanthin supplementation is best described as moderate-quality for a dietary supplement — multiple randomized controlled trials in humans across several outcome domains, but most trials are smaller than 100 subjects and durations are limited to 8-16 weeks. The strongest evidence exists for skin photoprotection and dermatology (Tominaga 2017 J Clin Biochem Nutr PMID 28529369 and related papers showing reduced wrinkle depth, improved skin elasticity, reduced photo-aging markers at 4-12 mg/day for 8-16 weeks), for eye health (particularly eyestrain from prolonged screen use, accommodative function, and pre-clinical data on dry eye and macular protection), for cardiovascular risk markers (Iwabayashi 2009 and subsequent trials showing reduced LDL oxidation, reduced hs-CRP, modest lipid improvements), for exercise recovery and performance (Kato 2020 and earlier work showing reduced muscle soreness, improved endurance, reduced markers of exercise-induced oxidative stress), and increasingly for cognitive outcomes (Satoh 2019 and related papers showing modest cognitive improvements in aging subjects). The depth of evidence across multiple outcome domains — with mechanistic plausibility from the antioxidant and anti-inflammatory effects — makes astaxanthin one of the better-evidenced carotenoid supplements. Safety is another area where astaxanthin distinguishes favorably from other carotenoids. Unlike beta-carotene (where the CARET and ATBC trials showed increased lung cancer risk in smokers with high-dose beta-carotene), astaxanthin has no comparable safety signal. Human trials at 4-40 mg/day have not identified significant adverse effects. Astaxanthin does not accumulate to produce orange skin discoloration at typical supplementation doses (unlike beta-carotene at high doses). Natural Haematococcus-derived astaxanthin has GRAS (Generally Recognized As Safe) status from the FDA at 12 mg/day, with higher doses in specific medical food applications. No drug interactions of clinical significance have been established at typical supplementation doses. The favorable safety profile combined with moderate efficacy evidence across multiple tissue domains makes astaxanthin a defensible supplement for the typical adult user interested in complete antioxidant support. BodyHackGuide's take: astaxanthin is among the best-evidenced, most mechanistically distinctive, and safest of the carotenoid supplements. At 4-12 mg/day (taken with fat-containing food), it provides meaningful antioxidant support with access to tissues (skin, eye, brain) that other carotenoids don't reach. The skin photoprotection evidence is particularly strong and clinically relevant for aging adults. The cardiovascular, exercise, and cognitive effects are modest but consistent. Cost is moderate ($15-30/month at typical doses). The main caveats: benefit is modest and pleiotropic rather than dramatic in any single outcome; the molecule is part of a broader antioxidant network and should not be relied on in isolation (vitamin C, vitamin E, polyphenols, omega-3 provide complementary support); and natural Haematococcus-derived product should be chosen over synthetic. For the typical adult interested in skin aging, eye health, cardiovascular antioxidant support, exercise recovery, or general anti-aging supplementation, 4-8 mg/day of natural astaxanthin is a reasonable addition to a complete stack. For intensive dermatologic, cardiovascular, or athletic applications, 8-12 mg/day is appropriate.

Also known as: Quercetin, 3,3',4',5,7-Pentahydroxyflavone, Quercetin aglycone, Quercetin dihydrate, Quercetin glycoside, Rutin, Quercetin-3-O-rutinoside, Quercetin-3-O-glucoside, Isoquercitrin, EMIQ, Enzymatically modified isoquercitrin, Alpha-glycosyl isoquercitrin, Quercetin phytosome, Quercefit, QuerceMax, QU995, Meriva-quercetin

Quercetin is a polyhydroxylated flavonoid compound (chemically 3,3',4',5,7-pentahydroxyflavone) that occurs widely in edible plants as both the free aglycone and a family of glycosides including rutin (quercetin-3-O-rutinoside), isoquercitrin (quercetin-3-O-glucoside), quercitrin (quercetin-3-O-rhamnoside), and multiple related sugar-conjugated forms. The basic flavonoid skeleton consists of two benzene rings (the A ring and B ring) connected by a three-carbon chain forming a third oxygen-containing ring (the C ring). Quercetin's distinguishing feature is five hydroxyl groups positioned at the 3, 5, 7, 3', and 4' carbons, which together give the molecule its strong antioxidant chemistry, its characteristic yellow color, and its broad spectrum of biological activities. Quercetin is one of the most abundant dietary flavonoids, providing roughly 15-40% of total flavonoid intake in typical Western diets. The richest dietary sources of quercetin include capers (180-230 mg per 100 g, the densest known source), red onions (20-50 mg per 100 g concentrated in the outer rings), yellow onions (10-20 mg per 100 g), shallots, kale (2-10 mg per 100 g), apples with skin (4-10 mg per 100 g with 90% in the peel), berries (cranberries 15-25 mg per 100 g, blueberries 2-8 mg per 100 g, blackcurrants 12-16 mg per 100 g), leafy greens, capers, buckwheat, fennel, cherry tomatoes, broccoli florets, green tea, black tea, and red wine. Fresh dill, cilantro, and hot green chili peppers are also rich sources. A typical Mediterranean-style diet with generous allium, berry, and tea consumption provides 15-40 mg of quercetin daily; supplement doses range from 250 mg (low) to 1500 mg (high) daily, an order of magnitude above typical dietary intake. Pharmacokinetic properties of quercetin are the single most important practical consideration when evaluating supplementation. Free quercetin aglycone has poor oral bioavailability (2-10%) due to low aqueous solubility, susceptibility to intestinal and hepatic Phase II conjugation (sulfation, glucuronidation, methylation), and rapid biliary and urinary elimination of the conjugates. Most dietary quercetin reaches systemic circulation as quercetin-3-glucuronide, quercetin sulfates, and methylated (isorhamnetin) derivatives rather than as free aglycone. These conjugates have their own biological activities — often different from, and sometimes opposing, those of the parent molecule — making the interpretation of in vitro data difficult. Enzymatically modified isoquercitrin (EMIQ, alpha-glycosyl isoquercitrin), quercetin phytosome (Quercefit, sunflower-lecithin quercetin), and quercetin bound to sunflower lecithin nanoparticles all substantially improve bioavailability by providing a glycoside form that is efficiently hydrolyzed at the intestinal brush border or by increasing apparent solubility. Bioavailability-enhanced forms can achieve 5-10-fold higher plasma concentrations than standard quercetin aglycone, which matters clinically because many reported benefits of quercetin require plasma concentrations above 1-2 micromol/L that unenhanced aglycone supplements struggle to achieve. The evidence base for quercetin supplementation spans multiple therapeutic areas. Cardiovascular applications include blood pressure reduction — Serban 2016 meta-analysis (PMID 27405810) pooled 7 trials and found that quercetin supplementation at doses of 500 mg daily or higher reduced systolic blood pressure by approximately 3.0 mmHg and diastolic by 2.6 mmHg in hypertensive subjects. Edwards 2007 tested quercetin 730 mg daily in stage 1 hypertensive men and found reductions of 7 mmHg systolic and 5 mmHg diastolic. Anti-inflammatory applications include mast cell stabilization via reducing histamine release and modulating cytokine production — quercetin has been used in allergic rhinitis, asthma, atopic dermatitis, and interstitial cystitis contexts with small-trial support. Respiratory applications include modest reductions in upper respiratory infection days with quercetin 1000 mg daily (Nieman 2009 supplement studies in endurance athletes). Metabolic applications include modest improvements in lipid profiles and markers of oxidative stress. A particularly consequential application is senolytic therapy. Quercetin combined with dasatinib (a tyrosine kinase inhibitor) has been developed as a senolytic cocktail — a combination that selectively eliminates senescent cells in aged or damaged tissues. Kirkland and colleagues at Mayo Clinic published foundational work (Zhu 2015 PMID 25754370) showing that the D+Q combination selectively killed senescent cells in vitro and improved physical function in aged mice. Hickson 2019 published the first human pilot trial (PMID 31542391) using D+Q in 14 patients with diabetic kidney disease, finding reductions in adipose tissue senescent cell markers. Subsequent trials are ongoing in idiopathic pulmonary fibrosis (LaPP trial), Alzheimer's disease, osteoarthritis, and frailty. The senolytic dosing protocol differs from continuous anti-inflammatory dosing: D+Q is typically administered as intermittent high-dose pulses (dasatinib 100 mg + quercetin 1000 mg daily for 3 consecutive days per month or quarter) rather than continuous daily use. Quercetin has also received attention as a zinc ionophore — a compound that facilitates zinc uptake across cell membranes. Dabbagh-Bazarbachi 2014 (PMID 25402583) characterized quercetin as a zinc ionophore in vitro. This mechanism became relevant during the COVID-19 pandemic when quercetin was proposed (alongside hydroxychloroquine and other ionophores) as a potential enhancer of intracellular zinc-mediated antiviral activity. Several small trials have tested quercetin in COVID-19 and upper respiratory infection contexts. Di Pierro 2021 (PMID 33853179) tested Quercefit phytosome 1000 mg daily in 152 mildly symptomatic COVID-19 patients and found reduced hospitalization rate and symptom duration. The evidence is preliminary and the clinical significance contested, but the mechanistic rationale has sustained research interest. For bodyhackguide.co users, quercetin occupies several intersecting places in the supplement landscape: allergy/histamine management (mast cell stabilization), cardiovascular prevention (blood pressure, endothelial function), senolytic aging protocols (D+Q combination), exercise and athletic performance (endurance and recovery support), and general antioxidant/anti-inflammatory stacking. It pairs naturally with bromelain (synergistic anti-inflammatory, often co-formulated), vitamin-c (regenerates oxidized quercetin and amplifies antihistamine effect), nettle leaf (traditional allergy support), fisetin (another senolytic flavonoid), curcumin (polyphenol synergy), resveratrol (stilbene-flavonoid polyphenol combination), zinc (ionophore substrate), EGCG (green tea polyphenol synergy), and NAC (glutathione support). The canonical recommendation for general use is 500-1000 mg daily of a bioavailability-enhanced form (EMIQ, phytosome) with food, tailored for specific indications (allergy, blood pressure, senolytic) as clinical context warrants.

Also known as: Apigenin, 4',5,7-Trihydroxyflavone, 5,7-Dihydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one, Chamomile flavone, Parsley apigenin, Celery apigenin, Apigenol, Versulin, Spigenin

Apigenin is a plant-derived flavone (4',5,7-trihydroxyflavone) that occurs widely in the plant kingdom as a constituent of leaves, flowers, and seeds. Structurally it is a flavone — distinguished from flavonols like quercetin and fisetin by the absence of a 3-hydroxyl group — giving it a simpler hydroxylation pattern with hydroxyl groups only at positions 4', 5, and 7. This structural simplicity underlies some of apigenin's distinctive biological properties, particularly its activity at GABA-A receptors (relevant to chamomile's traditional use as a calming herb) and its distinct profile of anticancer activity in preclinical studies. Apigenin is most concentrated in parsley (dried parsley contains up to 45 mg/g — exceptional by polyphenol standards), chamomile flowers and tea (approximately 5-16 mg/g dried chamomile flowers), celery (particularly the leaves), artichokes, and certain other culinary herbs. Other dietary sources with measurable apigenin content include oranges, grapefruit, onions, olives, and some teas. A standard cup of chamomile tea provides approximately 1-2 mg of apigenin, while dietary intake from parsley-rich Mediterranean cuisine may reach several mg daily. Typical Western dietary intake of apigenin averages below 1 mg per day, far below supplementation doses associated with claimed biological effects (50-500 mg daily). Modern scientific interest in apigenin derives from several converging lines of research. First, traditional herbal medicine has used chamomile (Matricaria chamomilla) for anxiolytic and calmative effects for centuries, and apigenin was identified as one of the key bioactive constituents responsible for these effects, with documented binding to benzodiazepine binding sites on GABA-A receptors. Second, a 2013 paper by Escande and colleagues (PMID 23603845) identified apigenin as an inhibitor of CD38 — the enzyme responsible for degrading NAD+ in mammalian cells — proposing apigenin as a tool for raising intracellular NAD+ levels by preventing NAD+ consumption. This work positioned apigenin as a complement to NAD+ precursors like nicotinamide riboside and nicotinamide mononucleotide. Third, extensive preclinical research has documented apigenin's anticancer effects in multiple tumor models, with mechanisms spanning cell cycle arrest, apoptosis induction, inhibition of angiogenesis, and modulation of inflammatory and growth factor signaling. Key scientific work includes Escande 2013 (PMID 23603845) demonstrating apigenin as a CD38 inhibitor with IC50 in the low micromolar range and showing in mice that apigenin administration elevated intracellular NAD+ levels in multiple tissues including liver, muscle, and white adipose tissue. Shukla and colleagues have extensively studied apigenin in prostate cancer models including Shukla 2014 (PMID 24957915) demonstrating efficacy in TRAMP mice. Camacho-Alonso 2019 (PMID 30904672) and related work addressed head and neck cancer applications. Gradolatto 2005 (PMID 15887220) characterized apigenin's oral pharmacokinetics in rats. Meyer 2006 (PMID 16706750) explored apigenin's anti-inflammatory mechanisms. Pharmacokinetically apigenin has modest oral bioavailability. In rat studies, oral bioavailability of free aglycone is approximately 20-25% with extensive glucuronidation and sulfation producing circulating conjugates. Plasma half-life is approximately 90 minutes for parent compound with longer half-lives for conjugates. Tissue distribution is broad with concentrations particularly in liver, kidney, intestine, and lung. Blood-brain barrier penetration is limited but sufficient for the GABA-A effects observed with chamomile-equivalent doses. Commercial supplementation typically uses apigenin from parsley, chamomile, or Passiflora incarnata (passionflower) extracts, standardized to 95-98% apigenin content. Liposomal and phytosome formulations provide enhanced bioavailability for therapeutic applications. The thematic positioning of apigenin in longevity and health supplementation spans three complementary use cases. First, as a CD38 inhibitor and thus an NAD+ preservation agent, apigenin is used alongside NAD+ precursors (NR, NMN) in longevity-oriented protocols. Second, as a GABA-A modulator, apigenin is used for sleep, anxiety reduction, and relaxation — in both chamomile tea form and higher-dose supplementation. Third, as a chemopreventive polyphenol with broad anti-inflammatory and cell-signaling effects, apigenin joins the polyphenol stack (quercetin, fisetin, curcumin) for general longevity and anti-inflammatory purposes. No single application has strong Phase 3 human clinical trial evidence, but the combined preclinical and mechanistic case is substantial. Commercial apigenin products vary in quality and standardization. Prefer products specifying source (parsley, chamomile, passiflora), confirmed purity (>95%), and third-party testing. Apigenin phytosome or liposomal formulations are increasingly available for users pursuing higher tissue concentrations. Typical supplementation doses range from 50 mg daily (low-dose sleep/mood support) to 500 mg daily (therapeutic dose for NAD+ preservation or anti-inflammatory goals).

Also known as: HT, 3,4-DHPEA, DOPET, Hytolive, Benolea

Hydroxytyrosol (3,4-dihydroxyphenylethanol, abbreviated HT or 3,4-DHPEA) is the smallest of the natural phenolic compounds produced by the olive tree and — pharmacologically — the single most important molecule in the olive polyphenol family. Chemically, hydroxytyrosol is a catechol: a benzene ring substituted with two adjacent hydroxyl groups at the 3' and 4' positions, connected through a two-carbon ethyl bridge to a terminal hydroxyl. This catechol motif is what makes hydroxytyrosol so biologically active — the same structural feature that gives catecholamines (dopamine, norepinephrine, epinephrine) their extraordinary chemical reactivity, and the same feature that gives EGCG, quercetin, and other catechol-bearing polyphenols their antioxidant kinetics. Hydroxytyrosol differs from dopamine by a single nitrogen: it is the "dopamine without the amine," a biosynthetic cousin of our endogenous neurotransmitters. This structural simplicity gives hydroxytyrosol exceptional radical-scavenging kinetics, tight affinity for LDL particles, ready crossing of the blood-brain barrier, and a pharmacology that bridges the polyphenol and catecholamine worlds. Hydroxytyrosol is found in olive leaves (up to several hundred mg/kg), olive fruit (200–4,000 mg/kg depending on cultivar and ripeness), olive mill wastewater (a major agricultural waste product that is one of the richest natural hydroxytyrosol sources and a focus of "circular bioeconomy" extraction technology), and — critically — in extra-virgin olive oil, where it appears both as free hydroxytyrosol and as the hydrolysis product of oleuropein during oil pressing, storage, and gastric passage. Premium high-polyphenol EVOO delivers 10–30 mg/kg of free hydroxytyrosol plus 100–500 mg/kg of hydroxytyrosol-releasing secoiridoids (oleuropein and oleuropein aglycone), which are hydrolyzed to hydroxytyrosol during digestion. This is why olive polyphenol content is reported as "hydroxytyrosol and its derivatives" in both EFSA regulation and the scientific literature — the hydroxytyrosol equivalent is the biologically meaningful unit. BodyHackGuide covers hydroxytyrosol as the most clinically validated polyphenol molecule in the olive family and — alongside its precursor oleuropein — the centerpiece of the Mediterranean-diet cardiovascular-protection mechanism. Hydroxytyrosol has the singular distinction of being the only natural polyphenol with an EFSA-approved cardiovascular health claim. Since 2012, the European Food Safety Authority has authorized the claim that "olive oil polyphenols contribute to the protection of blood lipids from oxidative stress" for any olive oil providing at least 5 mg of hydroxytyrosol and its derivatives per 20 g serving. No other polyphenol — not resveratrol, not EGCG, not curcumin, not any flavonoid — has received an approved EFSA Article 13.5 health claim. The EFSA decision was driven by the mechanistic depth and clinical reproducibility of the hydroxytyrosol oxidation-protection signal, anchored in the Covas 2006 EUROLIVE trial (PMID 16954359), which demonstrated dose-dependent reductions in circulating oxidized LDL in 200 healthy men given olive oils of increasing polyphenol content over three 3-week intervention periods. The clinical case for hydroxytyrosol rests on four main evidence pillars. First, the EUROLIVE trial established that olive polyphenol content — not fatty-acid composition — drives LDL oxidation protection. Second, the PREDIMED cardiovascular primary-prevention trial (Estruch 2013 PMID 23432189 and 2018 reanalysis PMID 29897866) demonstrated that adding high-polyphenol EVOO to a Mediterranean dietary pattern reduced major cardiovascular events by 30% over a median 4.8-year follow-up in 7,447 high-risk adults — an effect size matching high-intensity statin therapy and attributable primarily to the hydroxytyrosol/oleuropein polyphenol load of the intervention oil. Third, a growing body of smaller RCTs with direct hydroxytyrosol isolates (Hytolive, Benolea) at 5–50 mg/day has shown consistent signals for improved endothelial function, reduced oxidized LDL, modest blood pressure reduction, and improved lipid profile. Fourth, the mechanistic literature is unusually deep for a food polyphenol — hydroxytyrosol is one of the best-characterized dietary antioxidants in terms of pharmacokinetics, phase-II metabolism, Nrf2 activation, and direct radical-scavenging kinetics. Commercially, hydroxytyrosol is available as branded standardized ingredients from the olive supply chain. Hytolive (Genosa, Spain) is derived from olive mill wastewater via a patented aqueous extraction, standardized to 10–25% hydroxytyrosol, and has been the ingredient in most published hydroxytyrosol RCTs. Benolea (Frutarom/IFF) is olive-leaf-derived, standardized to similar hydroxytyrosol and oleuropein content. Olivactiv, Bioactive HT, and other branded HT ingredients occupy the same space. Consumer products range from low-dose cardiovascular blends (5–10 mg HT per capsule) to athletic-performance formulations (25–50 mg HT per serving). Prices run $0.20–$1.50 per mg of standardized HT, making dedicated hydroxytyrosol a premium-tier supplement relative to raw olive leaf extract or culinary EVOO. For most users, high-polyphenol EVOO (2–3 tablespoons daily) remains the most cost-effective and evidence-aligned hydroxytyrosol delivery vehicle; standardized HT supplementation is reserved for specific use cases where precise dose control, rapid absorption, or maximum polyphenol density is required. The hydroxytyrosol literature also extends beyond cardiovascular medicine into neuroprotection (Parkinson's disease models, cognitive aging studies), metabolic disease (insulin sensitization, hepatic lipid reduction in NAFLD models and early clinical trials), athletic performance (exercise-induced oxidative stress, muscle recovery), skin biology (UV protection, fibroblast protection from oxidative damage), and emerging anti-cancer mechanistic work (particularly in colorectal and breast cancer preclinical models). The neuroprotective story is notable because hydroxytyrosol crosses the blood-brain barrier more readily than most dietary polyphenols — a consequence of its small size, catechol structure, and modest lipophilicity — and because dopaminergic neurons in the substantia nigra are uniquely vulnerable to oxidative stress from dopamine auto-oxidation, which hydroxytyrosol (as a structural cousin of dopamine) may help buffer. Clinical evidence in neurological disease is still preclinical and early-translational, but the mechanistic rationale is strong. Hydroxytyrosol is best understood as the absorbed, bioavailable, pharmacologically active form of the olive polyphenol family. Oleuropein delivers it via hydrolysis; high-polyphenol EVOO delivers it as a matrix effect with oleocanthal and other secoiridoids; direct hydroxytyrosol isolates deliver it unmodified with maximum dose precision. For users who want a known, standardized polyphenol dose — particularly athletes, users with specific cardiovascular or metabolic indications, or those whose dietary EVOO intake is constrained — direct hydroxytyrosol supplementation is the cleanest approach. For routine cardiovascular protection within a Mediterranean pattern, high-polyphenol EVOO wins on cost, nutritional matrix, and cultural sustainability.

Also known as: (-)-Oleocanthal, Decarboxymethyl oleuropein aglycone, deacetoxy-ligstroside aglycone, p-HPEA-EDA

Oleocanthal — more precisely (-)-oleocanthal, or p-HPEA-EDA (para-hydroxyphenylethanol elenolic acid dialdehyde) — is the pungent phenolic secoiridoid that gives fresh, high-polyphenol extra-virgin olive oil its characteristic throat-biting, pepper-like sensation when swallowed. That single distinctive sensory cue, the urge to cough after a spoonful of premium EVOO, is a chemical reporter: it is the direct physiologic response to oleocanthal's selective activation of the TRPA1 receptor on pharyngeal sensory neurons, and it reliably signals a high-polyphenol oil. Chemically, oleocanthal is the monoaldehydic form of decarboxymethyl oleuropein aglycone — structurally a hydroxytyrosol ester of a rearranged elenolic acid fragment carrying two aldehyde groups. Unlike oleuropein, the bitter glycosylated secoiridoid found in olive leaves and young fruit, or hydroxytyrosol, the small catechol metabolite into which oleuropein hydrolyzes, oleocanthal carries a distinct and notable pharmacology: direct, non-selective cyclooxygenase (COX-1 and COX-2) inhibition with potency comparable to ibuprofen on a molar basis. This "ibuprofen-like" property was discovered serendipitously in 2005 by Gary Beauchamp and colleagues at the Monell Chemical Senses Center (Beauchamp et al., Nature 2005, PMID 16136122). Beauchamp, a sensory biologist who had sampled newly pressed Sicilian EVOO during a research trip, noticed that the throat-sting was identical to the sting he felt from the liquid ibuprofen used in sensory studies at Monell. That observation led to chemical identification of oleocanthal as the responsible compound and to a now-famous Nature paper demonstrating that oleocanthal dose-dependently inhibits COX-1 and COX-2 enzymes in cell-free assays at concentrations comparable to ibuprofen. A typical 50 mL daily serving of premium high-polyphenol EVOO delivers roughly 9–10 mg of oleocanthal — a dose that, given ibuprofen-equivalent potency, is roughly one-tenth of a single low-dose adult ibuprofen tablet (200 mg). This is not enough for acute analgesia, but it is plausibly enough for chronic anti-inflammatory effect when consumed daily — consistent with the Mediterranean diet's epidemiologic association with reduced rates of cardiovascular disease, cancer, and neurodegenerative disorders. BodyHackGuide covers oleocanthal as the third member of the olive polyphenol triumvirate alongside oleuropein (the bitter glycoside precursor) and hydroxytyrosol (the absorbed active metabolite). While hydroxytyrosol and oleuropein carry most of the antioxidant, endothelial, and cardiovascular signals attributed to olive polyphenols, oleocanthal carries a distinct anti-inflammatory mechanism (direct COX inhibition) and emerging signals in neurodegenerative disease and cancer that have attracted substantial preclinical research attention over the past two decades. Three major research threads have developed: (1) oleocanthal as a chronic-dose NSAID-like ingredient in the Mediterranean diet, potentially contributing to the diet's anti-atherogenic and anti-carcinogenic epidemiology; (2) oleocanthal as a promoter of amyloid-beta and tau protein clearance in Alzheimer's disease models (Abuznait 2013 PMID 23713657, Qosa 2015 PMID 25604610, and subsequent work from the Kaddoumi lab), with plausible relevance to the consistent inverse association between Mediterranean diet adherence and Alzheimer's risk in observational studies; and (3) oleocanthal as a lysosomal membrane permeabilization agent selectively cytotoxic to cancer cells (LeGendre 2015 PMID 25586900), a mechanism that spares non-cancerous cells and has generated interest in oleocanthal as an adjunct chemotherapy concept. Oleocanthal is chemically unstable outside the olive oil matrix. It is a dialdehyde with substantial electrophilic reactivity at both carbonyls, prone to polymerization, oxidation, and hydrolysis under aqueous conditions. In extra-virgin olive oil, it is stabilized by the anhydrous lipid matrix, other antioxidants (α-tocopherol, squalene, other polyphenols), and the darkness and oxygen-exclusion of proper storage. This chemical fragility is why pure oleocanthal supplements are essentially non-existent in the consumer market — unlike oleuropein (stable in olive leaf extract capsules) and hydroxytyrosol (stable in Hytolive and Benolea isolates), oleocanthal cannot be readily concentrated and packaged. The main commercial delivery vehicle for oleocanthal is — and likely will remain — high-polyphenol extra-virgin olive oil consumed fresh, within months of pressing, from properly-stored bottles. A few specialty olive-oil-matrix concentrate products exist (notably from research groups at Yale / the Gary Beauchamp lineage and from Spanish and Italian producers partnering with academic medical centers), but these are expensive, limited in availability, and generally marketed to research or clinical investigation contexts rather than consumer use. The clinical evidence base for oleocanthal as a discrete intervention (rather than as a component of a Mediterranean dietary pattern) is early-stage. No large-scale, adequately-powered randomized controlled trials have tested standardized oleocanthal-rich olive oil against oleocanthal-depleted olive oil or no intervention for hard clinical outcomes such as myocardial infarction, stroke, dementia onset, or cancer incidence. The strongest clinical signal comes from the PREDIMED trial (Estruch 2013 PMID 23432189, 2018 reanalysis PMID 29897866), which showed a 30% reduction in major cardiovascular events over a median 4.8-year follow-up in 7,447 high-risk adults randomized to Mediterranean diet with high-polyphenol EVOO. The EVOO used in PREDIMED was selected for high polyphenol content (oleocanthal + oleuropein + hydroxytyrosol + other secoiridoids), and the cardiovascular benefit is generally attributed to the whole polyphenol complex. Separating the oleocanthal contribution from the hydroxytyrosol and oleuropein contributions is methodologically difficult and has not been done in humans. Preclinical work — cellular assays, animal models, pharmacokinetic studies in humans — supports each mechanism individually, but the clinical story remains "Mediterranean diet / high-polyphenol EVOO works; oleocanthal contributes." The sensory signature of oleocanthal — the peppery throat bite, sometimes triggering a single cough on swallowing, that connoisseurs call "strong" or "intense" olive oil — is actually a reliable palate biomarker for polyphenol content. Andrewes and colleagues demonstrated in 2003 (published before oleocanthal had been structurally characterized by Beauchamp) that the TRPA1-mediated pharyngeal irritant was correlated with polyphenol content in olive oils. The sensory test is reproducible: swallow a small spoonful of olive oil, wait 10–30 seconds, and note any throat bite or tendency to cough. Bland, smooth, buttery oils are low-polyphenol. Oils that produce a distinct cough on swallowing are high-polyphenol and rich in oleocanthal. This is why premium EVOO producers cultivate the sensory intensity and why the Italian oil-connoisseur term "pizzica" (Italian for "pinches," referring to the throat bite) is a desired, not avoided, quality. For BodyHackGuide users, oleocanthal should be understood as a chronic-exposure, food-matrix molecule — not a supplement, not an acute analgesic, not a disease-targeted pharmaceutical. Its value comes from daily consumption of high-polyphenol EVOO as a culinary fat, typically 2–3 tablespoons (25–40 mL) per day, within a broader Mediterranean dietary pattern (vegetables, fish, legumes, whole grains, moderate red wine or none, minimal ultra-processed food). The mechanistic breadth (COX inhibition, amyloid and tau clearance, lysosomal membrane permeabilization in cancer cells, anti-inflammatory cytokine modulation, endothelial support via interactions with the broader olive polyphenol matrix) and the epidemiologic strength of Mediterranean diet adherence combine to make oleocanthal-rich EVOO one of the most defensible daily food-as-medicine recommendations in the contemporary nutrition evidence base.

Also known as: Sulforaphane, 1-Isothiocyanato-4-(methylsulfinyl)butane, (R)-1-Isothiocyanato-4-(methylsulfinyl)butane, SFN, Broccoli sulforaphane, Isothiocyanate, Glucoraphanin-derived sulforaphane, Avmacol sulforaphane, BroccoMax, Broccoli sprout extract

Sulforaphane is an organosulfur compound belonging to the isothiocyanate family, found predominantly in cruciferous vegetables (Brassicaceae family) including broccoli, broccoli sprouts, Brussels sprouts, cabbage, cauliflower, kale, bok choy, and collard greens. Sulforaphane has emerged as one of the most extensively studied phytochemicals of the modern era, primarily through the pioneering work of Paul Talalay and colleagues at Johns Hopkins University beginning in 1992. The compound is considered the premier dietary activator of the Nrf2/ARE pathway — the master cellular defense system that regulates endogenous antioxidant, detoxification, and anti-inflammatory gene expression. Chemically, sulforaphane (1-isothiocyanato-4-(methylsulfinyl)butane) is a small, polar molecule containing the characteristic isothiocyanate (-N=C=S) functional group that confers its biological reactivity. Importantly, sulforaphane is not present in cruciferous vegetables in its active form. Instead, plants store the inactive precursor glucoraphanin in vacuoles, separated from the enzyme myrosinase that converts glucoraphanin to sulforaphane. Upon plant tissue disruption (chewing, chopping, crushing), myrosinase comes into contact with glucoraphanin and hydrolyzes it to sulforaphane. Heat (cooking above 60-70°C) denatures myrosinase, preventing sulforaphane formation. This explains why raw or lightly-steamed broccoli produces much more sulforaphane than overcooked broccoli. Broccoli sprouts (3-day-old broccoli sprouts in particular) are the richest dietary source of sulforaphane precursor — containing 10-100 times more glucoraphanin per gram than mature broccoli. Talalay and colleagues' discovery of broccoli sprouts' exceptional concentration led to commercial sprout varieties (BroccoSprouts, branded Johns Hopkins sprouts) selected for high glucoraphanin content. Commercial broccoli sprout extract supplements typically standardize to glucoraphanin content with added active myrosinase to ensure in-gut conversion to sulforaphane. Brand products include Avmacol (Nutramax Laboratories), BroccoMax (Jarrow Formulas), and numerous other broccoli sprout extract supplements. The scientific foundation for sulforaphane was established by Talalay's laboratory beginning with a 1992 Proceedings of the National Academy of Sciences paper (PMID 1501249) identifying sulforaphane as a potent inducer of quinone reductase, a phase II detoxification enzyme. Subsequent work established sulforaphane as the primary bioactive small molecule in broccoli responsible for Nrf2 pathway activation, with effects persisting hours to days after a single exposure due to the covalent and long-lasting nature of Nrf2-Keap1 complex modification. Key clinical applications of sulforaphane include: chemoprevention research (breast, prostate, bladder, skin cancers via detoxification enzyme upregulation), autism spectrum disorder (Singh 2014 randomized trial showing behavioral improvements in young men with ASD), cardiovascular risk modification (LDL, blood pressure, endothelial function), type 2 diabetes (fasting glucose reduction), Helicobacter pylori eradication, air pollution protection, and general anti-inflammatory support. The Singh 2014 ASD trial (PMID 25288763) is particularly notable as the first rigorous double-blind randomized trial showing behavioral improvements in autism with a dietary-derived compound, though subsequent replication has been mixed. Pharmacokinetically sulforaphane has good oral bioavailability when properly formulated — approximately 70-80% absorption when active sulforaphane is delivered directly or when glucoraphanin is co-administered with active myrosinase. Half-life is approximately 1.9 hours. Metabolism occurs primarily through glutathione S-transferase conjugation followed by mercapturic acid pathway excretion. Plasma concentrations peak 1-3 hours after oral dosing with detectable sulforaphane-glutathione conjugates in urine for up to 24 hours. Tissue distribution is broad with particular accumulation in liver, kidney, gastrointestinal tract, and blood cells where Nrf2 targets are most abundant. The thematic positioning of sulforaphane in contemporary supplementation is as a foundational, evidence-backed phytochemical for general longevity, detoxification, anti-inflammatory, and chemoprevention support. It has stronger clinical evidence than most polyphenols for biomarker-level effects (oxidative stress markers, detoxification enzyme activity, inflammatory markers) and is backed by decades of mechanistic research. Its safety profile at dietary and supplemental doses is excellent. Commercial sulforaphane supplementation involves either (1) glucoraphanin-based products with added active myrosinase (Avmacol is the gold standard here, with validated in-vivo sulforaphane production), (2) sulforaphane-stabilized products delivering preformed active sulforaphane directly (less common; stability challenges), or (3) broccoli sprout extract without active myrosinase (less reliable conversion relying on gut microbiome). Users should strongly prefer products with documented active myrosinase and standardized glucoraphanin content (the "sulforaphane yield" specification). Typical supplementation doses range from 30 mg glucoraphanin daily (entry dose, yielding ~10-15 mg sulforaphane) to 200+ mg glucoraphanin daily (therapeutic dose, yielding 60-90 mg sulforaphane).

Also known as: Turmeric extract, Curcuma longa extract, Diferuloylmethane, Curcumin I, 1,7-bis-(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione, Meriva (phytosome), Theracurmin (nanoparticle), Longvida (SLCP), BCM-95 (turmeric essential oil complex), Novasol (liquid micellar), CurcuWIN, Tetrahydrocurcumin (THC, metabolite), Bisdemethoxycurcumin, Demethoxycurcumin

Curcumin is the principal bioactive polyphenol extracted from the rhizome of Curcuma longa (turmeric), constituting approximately 2-8% of dried turmeric root by weight along with two related curcuminoids (demethoxycurcumin and bisdemethoxycurcumin). The bright orange-yellow pigment has been used continuously for over 4,000 years in traditional Ayurvedic, Unani, and Siddha medicine for conditions ranging from wound healing and digestive disorders to arthritis and skin diseases, and it remains one of the most extensively studied natural compounds in modern biomedicine with over 20,000 PubMed-indexed publications and several thousand completed or ongoing clinical trials. Chemically, curcumin is a symmetric diferuloylmethane molecule (1,7-bis-(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione) with an enolized beta-diketone bridge between two aromatic rings bearing phenolic hydroxyl groups — this structure underlies both its antioxidant/electrophile-scavenging activity and its chemical instability. Curcumin degrades rapidly in neutral-to-alkaline aqueous conditions (half-life of minutes at physiological pH), is extensively conjugated to glucuronides and sulfates by phase II enzymes in the gut wall and liver, undergoes reductive metabolism to tetrahydrocurcumin and hexahydrocurcumin by gut bacteria and hepatic reductases, and is actively effluxed by intestinal P-glycoprotein. The net consequence of this unfavorable pharmacokinetic profile is that standard 95% curcuminoid extracts produce barely detectable free curcumin in plasma after oral dosing — a fact that invalidated much of the early curcumin research and delayed clinical translation for decades. The bioavailability problem has been addressed over the past 15 years through a generation of advanced delivery formulations that represent a genuine pharmaceutical advance rather than marketing: Meriva (Indena phytosome technology) complexes curcumin with soy or sunflower phosphatidylcholine, producing 29-fold increased bioavailability and strong clinical evidence in osteoarthritis (Belcaro 2010 PMID 21194249); Theracurmin (Theravalues nanoparticle dispersion) achieves 27-fold bioavailability increase and is the form used in the landmark Small 2018 cognitive aging trial (PMID 29204412); Longvida (Verdure Sciences solid-lipid curcumin particles) produces 65-100 fold increase and crosses the blood-brain barrier measurably; BCM-95 (Arjuna Natural turmeric essential oil complex) provides 7-fold increase; Novasol (liquid micellar) reaches 185-fold bioavailability in pharmacokinetic studies. These formulations have converted curcumin from a bench-science curiosity to a legitimate therapeutic with outcome trials supporting use in osteoarthritis, non-alcoholic fatty liver disease, metabolic syndrome, depression, cognitive aging, inflammatory bowel disease, and radiation dermatitis prevention. Clinical evidence is strongest for: Osteoarthritis (Daily 2016 meta-analysis PMID 27533649 pooled 8 RCTs showing effects comparable to NSAIDs for knee OA pain and function; Belcaro 2010 Meriva knee OA; Kuptniratsaikul 2014 PMID 24672232 head-to-head vs ibuprofen for knee OA showing non-inferiority); NAFLD/fatty liver (Rahmani 2016 PMID 27213821 demonstrated ultrasound resolution of hepatic steatosis; Panahi 2017 PMID 28195638 meta-analysis); Metabolic syndrome and type 2 diabetes (Chuengsamarn 2012 PMID 22773702 showed 9-month curcumin prevented T2D conversion in 16% of prediabetics vs placebo; Na 2014 meta-analysis PMID 24293002); Depression (Sanmukhani 2014 PMID 24259463 randomized trial showing efficacy comparable to fluoxetine; Ng 2017 meta-analysis PMID 28236605); Cognitive aging (Small 2018 PMID 29204412 18-month Theracurmin trial showing memory and attention benefits plus reduced amyloid/tau on PET imaging); Radiation dermatitis prevention (Ryan 2013 PMID 23814038 breast cancer radiation therapy). Evidence is weaker or negative for: curcumin as standalone cancer therapy (despite extensive preclinical data, large clinical trials have not demonstrated meaningful oncologic benefit); Alzheimer disease treatment (Ringman 2012 PMID 22818031 24-week trial was negative for cognition despite biomarker effects); long-term prevention endpoints (most trials are <12 months). The molecule's truly exceptional feature is its pleiotropy — curcumin modulates hundreds of molecular targets across inflammation, oxidative stress, mitochondrial function, apoptosis, angiogenesis, epigenetic regulation, and gut microbiome composition. Principal mechanisms include direct inhibition of NF-κB nuclear translocation (the master inflammatory transcription factor); suppression of COX-2 and 5-LOX (the enzymes inhibited respectively by NSAIDs and leukotriene-receptor antagonists); activation of Nrf2 (the master antioxidant transcription factor that induces HO-1, NQO1, glutathione-synthesis enzymes, and other cytoprotective genes); reduction of TNF-α, IL-1β, IL-6, and other pro-inflammatory cytokines; modulation of STAT3, AP-1, β-catenin, and other oncologically-relevant transcription factors; PPAR-γ agonism relevant to adipose and metabolic function; and emerging evidence for favorable gut microbiome modulation (increasing Bifidobacterium and Lactobacillus, reducing pathobiont proportions). Safety is exceptional: curcumin has a GRAS (Generally Recognized As Safe) designation from the FDA, has been used as a food spice in Indian cuisine at gram-level daily intakes for millennia without population-level toxicity signals, and has a clean safety profile in clinical trials up to 8 g/day for extended periods. The main practical safety considerations are drug interactions (CYP3A4 and P-glycoprotein substrate implications; warfarin INR effects), gallstone or bile-duct obstruction (curcumin stimulates bile flow and could theoretically worsen), and coordination with oncology during active chemotherapy. This entry covers curcumin's pharmacology, the bioavailability problem and formulation solutions, mechanism of action across inflammation/metabolism/neurobiology, the clinical evidence base by indication, drug interactions and safety, formulation selection for different goals, and integration with other evidence-based compounds including NAC, CoQ10, berberine, NMN, rapamycin, and glutathione.

Also known as: Berberine HCl, Berberine Hydrochloride, Umbellatine, Natural Metformin, Berberis Alkaloid, Dihydroberberine (DHB, reduced form), Coptisine (related alkaloid), Goldenseal Alkaloid

Berberine is an isoquinoline alkaloid — a naturally occurring plant secondary metabolite with a characteristic yellow color — extracted from the roots, rhizomes, stems, and bark of several plant genera including Berberis (barberry, Oregon grape), Coptis (goldthread), Hydrastis (goldenseal), Phellodendron (Amur cork tree), and Tinospora (guduchi). Its use in traditional medicine spans more than two millennia, with documented applications in Traditional Chinese Medicine (under the name Huang Lian Θ╗äΦ┐₧, primarily from Coptis chinensis), Ayurveda (from Berberis aristata, called Daruharidra or "tree turmeric"), Native American medicine (from goldenseal, Hydrastis canadensis), and Persian medicine (from Berberis vulgaris). Traditional indications emphasized gastrointestinal complaints — diarrhea, dysentery, intestinal infection — which turn out to align well with berberine's documented antimicrobial activity against bacteria, protozoa, and fungi. The modern pharmacologic investigation of berberine dates to the mid-20th century with early studies on antibacterial and antidiarrheal effects, but the explosion of contemporary interest followed the 2004 discovery by Kong and colleagues (PMID 15467988) that berberine lowers blood lipids through a mechanism involving LDL receptor upregulation. This finding redirected berberine research toward metabolic applications — diabetes, dyslipidemia, polycystic ovary syndrome, non-alcoholic fatty liver disease, and metabolic syndrome — and positioned berberine as a botanical analog to pharmaceutical metformin. The landmark Yin et al. 2008 randomized controlled trial (PMID 18397984) compared berberine 500 mg three times daily head-to-head with metformin 500 mg three times daily in 36 adults with newly-diagnosed type 2 diabetes over three months, finding comparable glycemic effects: HbA1c reduction of approximately 2 percentage points with berberine versus similar reduction with metformin, and with superior lipid effects (significant triglyceride and total cholesterol reductions exceeding what metformin produced). This single trial, though small, catalyzed the modern "natural metformin" marketing positioning that continues to drive berberine's commercial growth in the functional medicine and longevity supplement space. Since then, dozens of clinical trials and several meta-analyses have examined berberine across diabetes, dyslipidemia, metabolic syndrome, PCOS, hypertension, and various gastrointestinal indications. The accumulating evidence has generally supported berberine's metabolic effects but with important nuances: the bioavailability of oral berberine is less than 1%, meaning the vast majority of an ingested dose is never systemically absorbed; effects on distal organs therefore depend substantially on metabolites, gut microbiome modulation, and intestinal signaling rather than direct tissue exposure; effects on glucose and lipids are strong and reproducible but typically modest in magnitude (similar to metformin rather than superior to it in rigorous trials); meaningful pharmacokinetic drug interactions occur via cytochrome P450 inhibition, particularly CYP3A4 and CYP2D6, which must be considered for patients taking prescription medications metabolized by these pathways. Berberine has also entered the longevity and healthspan conversation as an AMPK activator — AMPK being one of the central nutrient-sensing pathways whose activation is believed to underlie at least some of the age-slowing effects of caloric restriction, metformin, and rapamycin-independent pathways. Whether berberine meaningfully extends healthspan in humans has not been demonstrated (the evidence for this is lower than for metformin, which itself has debated longevity evidence), but mechanistic rationale and safety profile have made it a common addition to longevity-oriented supplement stacks. Other prominent applications include: gastrointestinal applications in small intestinal bacterial overgrowth (SIBO) and irritable bowel syndrome, based on berberine's antimicrobial activity and favorable microbiome modulation; PCOS management, where Lan et al. 2015 (PMID 25935511) documented improvements in insulin resistance and menstrual regularity; non-alcoholic fatty liver disease, with trials showing hepatic steatosis reduction; and cholesterol management, where berberine's LDL receptor upregulation provides a statin-alternative for individuals with statin intolerance. The bioavailability problem has driven development of several alternative formulations: dihydroberberine (the reduced form, with theoretically superior absorption); phytosome formulations binding berberine to phosphatidylcholine to improve intestinal uptake; liposomal formulations; and combinations with P-glycoprotein inhibitors like silymarin to prevent efflux back into the intestinal lumen. Whether these formulations produce meaningfully superior clinical outcomes versus standard berberine HCl remains unclear, as most were developed for pharmacokinetic rather than efficacy endpoints. This entry covers berberine's mechanism (AMPK activation, gut-microbiome mediated effects, intestinal L-cell DPP-4 inhibition, lipid-modulating effects via LDL receptor and PCSK9 pathways); the clinical evidence base (glycemic effects, lipid effects, PCOS, NAFLD, weight, and gastrointestinal applications); the pharmacokinetic challenges (low bioavailability, CYP-mediated drug interactions, first-pass metabolism); formulation alternatives (dihydroberberine, phytosomes, liposomes); practical dosing considerations; and appropriate integration into metabolic, longevity, and gastrointestinal supplement protocols alongside metformin, NMN, TUDCA, NAC, CoQ10, curcumin, and other evidence-based interventions.

Also known as: EGCG, Epigallocatechin gallate, (-)-Epigallocatechin gallate, Epigallocatechin-3-gallate, Green tea catechin, Polyphenon E, Teavigo, Sunphenon, Catechin gallate, Green tea extract

Epigallocatechin gallate (EGCG) is the most abundant and biologically active catechin polyphenol in green tea (Camellia sinensis), typically constituting 50-80% of total catechins in dried green tea leaves. EGCG has emerged over the past two decades as one of the most extensively studied plant polyphenols, with clinical research spanning weight loss, cardiovascular health, glucose regulation, cancer chemoprevention, neuroprotection, and general antioxidant support. The compound has achieved broad commercial availability through both whole-leaf green tea and standardized green tea extract supplements, representing one of the best-characterized nutraceuticals in contemporary supplementation. Chemically, EGCG belongs to the flavan-3-ol subclass of flavonoids, consisting of an epigallocatechin core (a catechin with three hydroxyl groups on the B-ring) conjugated to gallic acid via an ester linkage at position 3. This gallate ester distinguishes EGCG from simpler catechins and substantially enhances its antioxidant and biological activity. EGCG's molecular structure — with eight hydroxyl groups and the gallate modification — gives it exceptional antioxidant capacity per mole and enables binding to multiple protein targets with micromolar-to-nanomolar affinity. Green tea has been consumed in East Asian cultures for thousands of years and is associated in population epidemiology with reduced cardiovascular disease, stroke, certain cancers, and overall mortality. The Ohsaki Study (Kuriyama 2006, PMID 16968850) followed 40,530 Japanese adults and showed green tea consumption (5+ cups daily) was associated with 16% reduced cardiovascular mortality compared to <1 cup daily. Similar associations have been replicated across multiple East Asian population cohorts. EGCG is considered the primary bioactive component responsible for these health associations, though green tea contains multiple other bioactive catechins (epicatechin, epigallocatechin, epicatechin gallate), L-theanine, caffeine, and other constituents that also contribute. Commercial EGCG supplementation evolved from (1) whole green tea leaves and powder (matcha), (2) brewed green tea beverage consumption, (3) standardized green tea extracts (typically 50-80% polyphenols, 25-50% EGCG), (4) highly purified EGCG preparations (90-98% pure). Notable branded ingredients include Teavigo (decaffeinated high-EGCG extract), Sunphenon (standardized green tea polyphenols), and Polyphenon E (a pharmaceutical-grade standardized green tea extract used in clinical research). Commercial finished products range from low-dose green tea extract (200-400 mg total polyphenols) to high-dose pure EGCG capsules (400-800 mg per serving). Clinical research on EGCG spans hundreds of randomized trials and meta-analyses. Key findings include: modest weight loss and metabolic improvement in overweight/obese adults (meta-analyses show 1-3% weight reduction versus placebo), reduction in LDL cholesterol and blood pressure in hyperlipidemic or hypertensive adults, improvement in glucose metabolism and HbA1c in prediabetic/type 2 diabetic populations, reduced oxidative stress markers and inflammation, reduction in some cancer biomarkers (particularly prostate cancer PSA), potential neuroprotective effects in early-stage neurodegenerative research, and weight management adjunct in various conditions. Critical safety considerations: EGCG at high doses (particularly in fasted state and as concentrated extracts) can cause hepatotoxicity — liver enzyme elevations and, rarely, severe liver injury requiring transplant. The European Food Safety Authority (EFSA 2018) has recommended limiting daily EGCG intake from supplements to 800 mg daily or less, and preferably taking with food rather than fasted. The hepatotoxicity appears related to pro-oxidant effects of high EGCG concentrations on hepatocytes and may involve susceptible genetic polymorphisms. Green tea beverage consumption at typical dietary levels (1-5 cups daily) is not associated with hepatotoxicity — the concern is specifically with concentrated high-dose supplement use. Pharmacokinetically EGCG has low oral bioavailability — approximately 0.1-1.5% in typical conditions, with extensive first-pass glucuronidation and methylation. Plasma concentrations peak 1-2 hours after oral dosing. Bioavailability enhancement strategies include liposomal, phytosome, and micellar formulations (providing 3-8x improved absorption), co-administration with piperine (minor enhancement), fasted administration (enhances absorption but increases hepatotoxicity risk), and combination with other catechins (modest enhancement through microbial metabolism). Tissue distribution is broad including liver, kidney, intestine, prostate, and brain. The thematic positioning of EGCG spans multiple use cases. For cardiovascular and metabolic effect, EGCG (as green tea extract or purified) at 200-500 mg daily provides documented biomarker improvements. For weight management adjunct, EGCG combined with caffeine and caloric modification produces modest enhanced weight loss. For cancer chemoprevention, EGCG has extensive preclinical evidence with limited clinical confirmation. For general longevity and antioxidant support, EGCG sits alongside other polyphenols as a foundational supplementation choice. Most users benefit more from regular green tea consumption than from concentrated extract supplementation, with concentrated extracts reserved for specific therapeutic targets. Commercial product selection involves important trade-offs: whole green tea or matcha preserves the natural matrix of catechins, theanine, and other compounds with lower EGCG per serving but higher safety margin; standardized green tea extract provides higher EGCG doses in convenient capsule form; highly purified EGCG preparations maximize dose efficiency but carry higher hepatotoxicity risk. Users should select based on their specific goals, and prefer products with third-party testing and reputable brands given the hepatotoxicity concerns with adulterated or poorly-manufactured concentrated extracts.

Also known as: NAD Plus, Nicotinamide Adenine Dinucleotide, NAD

NAD+ (nicotinamide adenine dinucleotide, oxidized form) is a pyridine dinucleotide coenzyme essential to energy metabolism, DNA repair via PARP enzymes, sirtuin-mediated gene regulation, and calcium signaling via CD38. Intracellular NAD+ declines by roughly 50% between ages 40 and 70 in most tissues studied, and restoring NAD+ levels with oral precursors (nicotinamide riboside NR, nicotinamide mononucleotide NMN, nicotinamide NAM) or intravenous NAD+ is one of the most-studied interventions in longevity research. Clinical trials with NR (Chromadex's Niagen) have demonstrated dose-dependent increases in peripheral blood mononuclear cell NAD+ up to 142% at 1,000 mg/day and a favorable safety profile across doses up to 2,000 mg/day. Direct IV NAD+ is used in some longevity and addiction medicine clinics at 250-1,500 mg per session; oral NAD+ itself has poor bioavailability and is generally inferior to its precursors. Regulatory status varies: NR is a legal dietary ingredient in the US and EU; NMN was removed from US dietary supplement status in 2022 but is widely available through other markets; IV NAD+ is compounded at specialty pharmacies.

Also known as: Nicotinamide Mononucleotide, beta-NMN, β-NMN, β-Nicotinamide mononucleotide, NMN-C, Uthever

Nicotinamide mononucleotide (NMN) is a naturally occurring nucleotide derived from ribose and nicotinamide, serving as the direct biosynthetic precursor to nicotinamide adenine dinucleotide (NAD+) via a single enzymatic step catalyzed by nicotinamide mononucleotide adenylyltransferase (NMNAT). NMN is found in small quantities in foods including broccoli, cabbage, cucumber, edamame, avocado, tomato, and raw beef, typically in microgram-to-low-milligram quantities per serving — far below the 250-1000 mg doses used in supplementation research. The structure — a ribonucleotide composed of ribose-5-phosphate linked to nicotinamide via a beta-N-glycosidic bond — makes NMN one step closer to NAD+ in the biosynthetic pathway than nicotinamide or nicotinamide riboside (NR), which are two and one-plus-ATP step further removed respectively. NMN's rise from obscure biochemistry reagent to one of the most commercially prominent longevity supplements began with preclinical work in the Sinclair and Imai laboratories documenting NAD+-lowering effects of aging and NAD+-repletion benefits of NMN administration in mice. Mills et al. 2016 (PMID 28068222) demonstrated that 12 months of oral NMN (100-300 mg/kg) in aged mice prevented age-associated physiologic decline including weight gain, insulin sensitivity deterioration, eye function decline, muscle function decline, and bone density loss. Similar findings came from multiple rodent studies over 2013-2020 establishing NMN as a consistent NAD+-raising intervention with broad preclinical benefit across age-related pathologies. The first human pharmacokinetic study of NMN was conducted by Irie and colleagues in 2020 (PMID 32446072), administering single oral doses of 100, 250, and 500 mg NMN to ten healthy Japanese men aged 40-60 and documenting dose-proportional increases in plasma NMN and its downstream metabolites with no serious adverse events — establishing oral NMN's basic safety and pharmacokinetics in humans. Yoshino and colleagues 2021 (PMID 33888596) conducted the first human efficacy RCT, randomizing 25 prediabetic postmenopausal women with overweight/obesity to 10 weeks of oral NMN 250 mg/day versus placebo. The trial documented significant improvement in skeletal muscle insulin sensitivity (measured by hyperinsulinemic-euglycemic clamp) with NMN versus placebo, and increased skeletal muscle expression of genes related to muscle remodeling. The Yoshino 2021 trial remains the landmark early human NMN efficacy study despite its small sample size. Subsequent human trials have examined NMN across a range of populations and outcomes with varying results: Yamamoto 2022 examined NMN in older adults with mixed metabolic outcomes; Pencina 2023 (PMID 37378613) provided a 6-week dose-ranging safety study; Connell et al. 2023 (PMID 37058488) conducted a meta-analysis of available NMN human trials through early 2023. The emerging human evidence base supports NMN's safety across tested dose ranges (up to 1,000 mg/day for short-term use in small trials) and provides suggestive but not yet definitive evidence for metabolic, cardiovascular, and musculoskeletal benefits. The evidence base remains substantially behind the marketing claims, with many commercial NMN products citing preclinical mouse data or extrapolating from NAD+ biology rather than demonstrating human RCT outcomes. Regulatory status: NMN was marketed in the US as a dietary supplement under DSHEA from approximately 2014 onward. In late 2022, the FDA issued a preliminary determination that NMN is not a lawful dietary supplement because it had been studied as a drug prior to being marketed as a supplement, potentially excluding it from DSHEA protection. This triggered significant industry concern and some reformulation. The regulatory situation has continued to evolve through 2025-2026 with industry litigation and FDA enforcement activity varying by product and distributor. As of early 2026, NMN remains widely available from many supplement retailers despite the regulatory uncertainty. NAD+ biochemistry context: NAD+ is a central coenzyme in cellular metabolism, participating in hundreds of enzymatic reactions spanning energy metabolism (as electron carrier in oxidative phosphorylation), DNA repair (as substrate for poly-ADP-ribose polymerase or PARP enzymes), and signaling (as substrate for sirtuins and CD38). Cellular NAD+ levels decline with aging across multiple tissues and organisms, with the decline implicated in age-associated mitochondrial dysfunction, impaired DNA repair, reduced sirtuin activity, and compromised cellular resilience. The NAD+ "boosting" hypothesis — that restoring youthful NAD+ levels through precursor supplementation could slow or reverse age-related decline — has driven extensive investment in NMN and the related NAD+ precursor nicotinamide riboside (NR, marketed as Niagen). NMN and NR are often discussed as competing or complementary precursors; both have human safety data and both raise NAD+ in humans, though the optimal dose, route, and clinical context remain areas of active research and commercial dispute. This entry covers NMN's biosynthesis and relationship to the NAD+ salvage pathway; the human and preclinical evidence base for metabolic, cardiovascular, and cognitive applications; dose-response considerations and the rational approach to supplementation; the oral versus sublingual versus injectable administration route debate; the evolving regulatory landscape; appropriate integration into complete longevity protocols alongside metformin, rapamycin (when available), NAD+, and lifestyle interventions; and honest framing that despite strong mechanistic rationale and good safety data, definitive evidence for meaningful longevity or healthspan extension in humans remains to be established.

Also known as: PQQ, Pyrroloquinoline quinone, Methoxatin, PQQ disodium salt, Pyrroloquinoline quinone disodium, BioPQQ, MGCPQQ, PureQQ, 4,5-dihydro-4,5-dioxo-1H-pyrrolo[2,3-f]quinoline-2,7,9-tricarboxylic acid, PQQH2, PQQ hydroquinone, Reduced PQQ, Coenzyme PQQ, Quinone cofactor, o-Quinone cofactor

Pyrroloquinoline quinone (PQQ, methoxatin) is a small tricyclic o-quinone originally discovered in 1964 as the prosthetic group of bacterial methanol dehydrogenase. In methylotrophic and methanotrophic bacteria (organisms that live on methane or methanol), PQQ serves as a redox cofactor for several quinoprotein dehydrogenases — methanol dehydrogenase, glucose dehydrogenase, ethanol dehydrogenase — catalyzing two-electron oxidations of alcohols, aldehydes, and sugars via stable semiquinone intermediates. PQQ is an ancient cofactor, chemically simpler than NAD+ or FAD, and its discovery sparked decades of interest in whether PQQ plays a comparable role in mammalian biology. The answer has been contested and remains incompletely resolved: PQQ is present in mammalian tissues at low concentrations, is found in a wide range of foods (fermented soy, parsley, green tea, kiwi, papaya, breast milk), produces measurable deficiency syndromes in strict PQQ-restricted animal diets, and has been proposed as a novel B vitamin — yet no mammalian apo-enzyme requiring PQQ as a prosthetic group has been definitively characterized, and PQQ's essentiality in humans is not accepted by the IOM or EFSA. This creates a regulatory and scientific ambiguity similar to boron's — PQQ may have biological activity in mammals, but it does not meet formal essentiality criteria, and the evidence for supplementation benefit in healthy humans is mechanistically suggestive but clinically limited. The chemistry of PQQ is distinctive and underlies much of its proposed biological activity. The tricyclic aromatic structure contains an ortho-quinone (adjacent carbonyl groups) that can accept electrons to form a semiquinone radical intermediate and then a fully reduced hydroquinone (PQQH2). Unlike many quinones, PQQ undergoes this redox cycling with exceptional catalytic efficiency — a single PQQ molecule can go through an estimated 20,000-100,000 redox cycles before degradation, compared to approximately 4 cycles for vitamin C or 100-200 for other polyphenols before oxidative destruction. This redox stability is the foundation of PQQ's proposed antioxidant role. Additionally, the ortho-quinone chemistry enables PQQ to react with amino groups on amino acids and proteins, forming quinoprotein adducts — a mechanism relevant to the bacterial quinoprotein enzymes and potentially to mammalian signaling. The three carboxylic acid groups make PQQ water-soluble, ionized at physiologic pH, and well-suited for renal excretion. PQQ was proposed as a novel B vitamin in a 2003 Nature paper (Kasahara 2003 PMID 12679798) based on studies of mice fed PQQ-deficient diets and analysis of the aminoadipic semialdehyde dehydrogenase (AASDH) enzyme system. The claim was that PQQ was an essential dietary factor required for AASDH activity. Subsequent critical reevaluation and the authors' own follow-up work determined that AASDH does not use PQQ as a cofactor in mammals, and the claim of PQQ being a new B vitamin was not validated. However, PQQ-deficient diets in mice do reliably produce a reproducible syndrome — growth impairment, reproductive failure, skin fragility, impaired neonatal survival — first described by Killgore, Smidt, Steinberg 1989 and refined by subsequent work (Stites 2000 PMID 10888956; Rucker 2009 PMID 19234001). This syndrome is ameliorated by dietary PQQ supplementation. Whether this represents true essentiality (deficiency syndrome as with a vitamin) or a pharmacologic effect of a biologically active dietary compound remains debated. The phenotype is subtle enough that formal nutritional essentiality has not been declared, but PQQ is not a trivial dietary factor either. PQQ is widely distributed in foods, though typically at low concentrations. The highest documented food concentrations are in fermented soybeans (natto) at approximately 61 ng/g, parsley at 34 ng/g, green tea at 30 ng/g, kiwi at 27 ng/g, papaya at 27 ng/g, spinach at 22 ng/g, tofu at 24 ng/g, dark chocolate at 9 ng/g, and human breast milk at approximately 140-180 ng/mL (substantially more concentrated than cow's milk at 4-17 ng/mL, suggesting physiologic concentration into breast milk). The presence in breast milk at meaningful concentrations is one argument for PQQ being a biologically important dietary factor. Typical Western dietary intake is estimated at 0.1-1 mg/day, though accurate intake data are limited because few food composition databases include PQQ. The supplementation dose range (10-40 mg/day) is approximately 10-400 times typical dietary intake, placing supplementation firmly in the pharmacologic rather than nutritional replacement range. This is similar to the situation for many polyphenols and flavonoids — dietary exposure is modest, supplementation achieves levels that may produce measurable biological effects, but the relationship to dietary deficiency is indirect. At supplementation doses, PQQ is absorbed with moderate efficiency (estimated 20-40%), circulates briefly in plasma, distributes to tissues (with notable concentration in kidney, liver, heart, and brain), and is excreted via urine predominantly as intact PQQ or PQQ conjugates. The most commercially relevant application of PQQ supplementation is mitochondrial biogenesis. Chowanadisai 2010 J Biol Chem PMID 20022988 demonstrated in mouse and human cell culture that PQQ at physiologic and supraphysiologic concentrations activates the PGC-1α (peroxisome proliferator-activated receptor gamma coactivator 1-alpha) pathway, the master regulator of mitochondrial biogenesis. PGC-1α activation produces increased mitochondrial DNA content, increased expression of mitochondrial proteins (NRF1, NRF2, TFAM), and functionally increased cellular respiratory capacity. This mechanism underlies the marketing claim that PQQ produces "new mitochondria" — an oversimplification of a real mechanism. Whether PGC-1α activation in isolated cell culture translates to measurable mitochondrial expansion in human tissue during supplementation is an open question; human studies of mitochondrial biomarkers with PQQ are limited. The second major supplementation claim is cognitive/memory enhancement. Nakano 2012 Functional Foods in Health and Disease trial in 41 middle-aged and elderly Japanese subjects supplemented with 20 mg PQQ/day for 12 weeks showed improvements in a cognitive battery (particularly in subjects with lower baseline cognitive function). Nakano 2009 had shown similar effects in a smaller pilot. Itoh 2016 PMID 26857805 examined sleep and stress and found modest improvements in sleep quality and stress markers. These are small Japanese trials, not replicated in large Western populations. The mechanism is proposed to involve mitochondrial function, NGF (nerve growth factor) stimulation, and antioxidant effects on neural tissue. The third area of supplementation claim is cardiovascular — antioxidant protection, improved LDL oxidation resistance, and in pre-clinical models, protection against ischemia-reperfusion injury (Tao 2007 PMID 18048410 showed PQQ protection of rat hearts in I/R model). No large human cardiovascular outcome trial has been conducted. BodyHackGuide's take: PQQ is mechanistically interesting and biologically plausible, with a wide safety margin and low toxicity. The mitochondrial biogenesis mechanism is supported by good cell biology data. The human clinical data, however, are limited — a handful of small Japanese trials mostly in cognitive outcomes, limited Western replication, and no large endpoint trials. At 10-20 mg/day (the typical supplementation dose, as BioPQQ disodium salt or equivalent), PQQ is safe, the theoretical mechanism is sound, and modest benefits on cognition and energy have been reported by some users. Whether this translates to meaningful health improvement for the typical user is uncertain. PQQ is a reasonable addition to a mitochondrial-support stack (with CoQ10, alpha-lipoic acid, creatine, exercise) but it is not a foundational intervention. The cost is moderate ($30-60/month at typical doses), making it one of the more expensive trace cofactors to supplement. For users interested in the mitochondrial biogenesis angle, PQQ 10-20 mg/day for 3-6 months as a trial, alongside the foundational mitochondrial stack, is a defensible approach. For users without specific mitochondrial or cognitive concerns, PQQ is probably not a high-priority supplement.

Also known as: CoQ10, Coenzyme Q, Ubiquinone, Ubidecarenone, Ubiquinol, Reduced CoQ10, Kaneka Q10, Kaneka QH, MitoQ, CoQH2, Q10

Coenzyme Q10 (CoQ10), also known as ubiquinone-10, ubidecarenone, or simply "coenzyme Q," is a lipid-soluble benzoquinone compound with a 50-carbon isoprenoid side chain (decaprenyl tail) that anchors it within the inner mitochondrial membrane. Its name — ubiquinone — reflects its ubiquitous distribution across all animal and most bacterial tissues, where it performs two critical biological functions: electron transport in oxidative phosphorylation and lipid-phase antioxidant defense. Every cell that contains mitochondria depends on CoQ10 for ATP production, and every cell with a membrane benefits from CoQ10's capacity to intercept lipid peroxidation. The molecule exists in a reversible redox couple: the oxidized quinone form (ubiquinone, Q) accepts two electrons and two protons to become the fully reduced hydroquinone (ubiquinol, QH2), and the interconversion sits at the functional heart of mitochondrial bioenergetics. Humans synthesize CoQ10 endogenously via the mevalonate pathway — the same pathway that produces cholesterol, dolichol, and isoprenoid groups for protein prenylation. Tyrosine contributes the benzoquinone head ring, and farnesyl pyrophosphate contributes to elongation of the decaprenyl tail through sequential additions of five-carbon isoprene units catalyzed by trans-prenyltransferase and polyprenyl-4-hydroxybenzoate transferase, with final assembly and modifications occurring in mitochondria. This shared upstream pathway explains one of CoQ10's most discussed clinical interactions: HMG-CoA reductase inhibitors (statins), used by tens of millions of people for cardiovascular disease prevention, reduce endogenous CoQ10 synthesis by 30-50% because they block the pathway upstream of both cholesterol and CoQ10 production. Whether this statin-induced CoQ10 depletion is clinically significant — particularly for statin-associated muscle symptoms — has been one of the most contested nutritional-pharmacology debates of the past two decades, with some meta-analyses supporting clinically meaningful benefit from CoQ10 supplementation and others finding no effect on muscle symptoms. Functionally, CoQ10's most important role is at the center of the electron transport chain (ETC). Complex I (NADH dehydrogenase) and Complex II (succinate dehydrogenase) both donate electrons to ubiquinone, reducing it to ubiquinol, which then shuttles electrons to Complex III (cytochrome bc1 complex) before they ultimately reach oxygen at Complex IV and generate water. The movement of electrons through this sequence is coupled to proton pumping across the inner mitochondrial membrane, establishing the electrochemical gradient that Complex V (ATP synthase) uses to phosphorylate ADP to ATP. A cell cannot make mitochondrial ATP without CoQ10, full stop. Tissues with the highest energy demand — heart, kidney, liver, skeletal muscle, brain — contain the highest CoQ10 concentrations, which is why CoQ10 supplementation has been most intensively studied for heart failure and neurodegenerative diseases. Beyond bioenergetics, CoQ10 is arguably the most important lipid-phase antioxidant in human biology. Unlike water-soluble antioxidants (vitamin C, glutathione), CoQ10 partitions into membrane lipid bilayers and LDL particles where it intercepts peroxyl radicals, prevents initiation and propagation of lipid peroxidation chains, and regenerates vitamin E (α-tocopherol) after it has been oxidized to tocopheroxyl radical. The reduced form ubiquinol is the antioxidant-active species; after donating electrons to quench lipid radicals, it becomes ubisemiquinone and then ubiquinone, and the cellular machinery reduces it back. Because circulating LDL contains roughly 1 molecule of ubiquinol per LDL particle alongside 6-8 molecules of vitamin E, CoQ10 is a key determinant of LDL's resistance to oxidation — relevant to atherosclerosis biology even if direct cardiovascular outcome trials have not captured this mechanism cleanly. The landmark clinical trial for CoQ10 is Q-SYMBIO (Mortensen et al 2014, PMID 25282031), a double-blind randomized trial of 420 patients with NYHA class III-IV heart failure receiving CoQ10 100 mg three times daily vs placebo for two years. CoQ10 supplementation reduced major adverse cardiovascular events by 43% — a striking effect size unmatched by most cardiovascular pharmaceuticals studied in similar populations — with concurrent reductions in hospitalizations and mortality. This trial, combined with the earlier Morisco 1993 and Mortensen 1990 trials, has established CoQ10 as part of integrative heart failure management, though the mainstream cardiology community has been slow to incorporate it. CoQ10 has additional evidence of varying strength for migraine prevention (Sandor 2005, PMID 15728289), statin-associated muscle symptoms (mixed), fertility (both male and female), age-related macular degeneration, periodontal disease, and Parkinson's disease (positive pilot data, negative large trials). For BodyHackGuide readers, CoQ10 is one of the most important foundational supplements in the mitochondrial-support category, with particular relevance for anyone over 40 (endogenous CoQ10 production declines with age), anyone on statin therapy, anyone with a family history of heart failure or cardiomyopathy, athletes seeking mitochondrial performance enhancement, patients with migraines, and anyone pursuing complete antioxidant tuning. This page covers the biochemistry, the heart failure and migraine evidence, ubiquinone vs ubiquinol form selection, absorption tuning (CoQ10 has notoriously poor bioavailability without lipid co-ingestion or specialized formulations), stacking with ALA and PQQ for mitochondrial support, and practical dosing across indications.

Also known as: GSH

Glutathione is the body's most abundant intracellular antioxidant — a three-amino-acid peptide made of glutamate, cysteine, and glycine (Glu-Cys-Gly), present in millimolar concentrations inside every cell of your body. It is not a research peptide in the same sense as BPC-157 or Semax; it is a fundamental metabolic molecule that your liver synthesizes constantly from its amino acid components. The interest in supplemental glutathione stems from the observation that tissue GSH levels decline with age, with chronic disease, with oxidative stress, and with certain medications — and that restoring GSH levels may improve outcomes in conditions ranging from fatty liver disease to Parkinson's disease to chemotherapy-induced toxicity. Chemically, glutathione exists in two interconvertible forms: the reduced form (GSH), which is the antioxidant-active form with a free thiol (-SH) group, and the oxidized form (GSSG), in which two GSH molecules are linked by a disulfide bond. The ratio of GSH to GSSG in a cell is one of the most reliable biochemical markers of oxidative stress — a healthy cell maintains a GSH:GSSG ratio of roughly 100:1, while cells under oxidative stress see this ratio collapse. The dynamic regeneration of GSH from GSSG by the enzyme glutathione reductase (using NADPH as the reducing equivalent) is one of the core redox cycles of cellular metabolism (Lu, 2013). Glutathione has a broad range of biological functions that go beyond simple antioxidant activity. It directly scavenges reactive oxygen species. It is a cofactor for glutathione peroxidases, the enzymes that detoxify hydrogen peroxide and lipid peroxides. It is the substrate for glutathione-S-transferases, which conjugate toxins and xenobiotics to glutathione for elimination — this is the core of Phase II liver detoxification for everything from acetaminophen to heavy metals to alcohol metabolism byproducts. It regulates cell signaling through protein glutathionylation. It supports mitochondrial function, particularly in complex I and complex III of the electron transport chain. It is essential for lymphocyte function and immune system activity. It is the key reducing agent for vitamin C recycling and for the proper function of vitamin E (Forman et al., 2009). The practical problem with supplementing glutathione is bioavailability. Oral glutathione is largely broken down by gastrointestinal peptidases before it can be absorbed intact, and even the fraction that enters systemic circulation has difficulty crossing cell membranes to reach intracellular compartments where it is needed. This is the central question that has driven the development of alternative formulations: intravenous glutathione (bypasses GI degradation but still has cellular uptake limits), liposomal glutathione (protects the molecule in the gut and may improve uptake), intranasal glutathione (bypasses first-pass metabolism, delivers directly to brain via olfactory/trigeminal routes), nebulized glutathione (delivers to lung tissue), and glutathione precursors like N-acetylcysteine (NAC), which provides the rate-limiting cysteine for endogenous synthesis (Sechi et al., 1996, Schmitt et al., 2015). Clinical evidence for glutathione supplementation is strongest in a few specific contexts. Acetaminophen overdose is the textbook case — N-acetylcysteine administration to replenish hepatic GSH is standard of care and saves lives, with an evidence base spanning decades. Nonalcoholic fatty liver disease (NAFLD) has seen multiple small trials of oral and IV glutathione showing improvements in ALT, oxidative stress markers, and liver histology. Parkinson's disease has a growing body of research on intranasal and IV glutathione, based on observations that Parkinson's patients have reduced GSH in the substantia nigra and that GSH supplementation may have neuroprotective and symptomatic effects. Cystic fibrosis has trials of inhaled glutathione for lung function improvement. Chemotherapy-induced neuropathy and ototoxicity has trials suggesting IV glutathione may reduce certain chemotherapy side effects (Testa et al., 2016, Honda et al., 2017). The research peptide and longevity community uses glutathione much more broadly than these evidence-supported indications. Common use patterns include: general anti-aging and longevity support, skin brightening and melanin reduction (popular in Asian markets), hangover prevention and recovery, support during heavy training or physical stress, liver support during alcohol use or medication courses, "detox" protocols (a vague concept but biochemically coherent for glutathione's role in Phase II conjugation), and as a supportive agent in fatigue syndromes, chronic Lyme disease, and environmental illness. Evidence for these uses ranges from suggestive to entirely anecdotal. The mythology around IV glutathione "detox" has outpaced the evidence. True detoxification — removal of specific toxins through Phase II conjugation — is a well-characterized biochemical process that glutathione is central to. But the popular concept of "flushing toxins" through IV glutathione drips is largely marketing built on the real biochemistry. Similarly, the skin-brightening use of IV glutathione is documented and real — glutathione inhibits tyrosinase and shifts melanin synthesis from eumelanin (dark) toward pheomelanin (light) — but it comes with safety concerns the marketing rarely mentions, especially in the high-dose IV protocols marketed in beauty clinics, which the FDA has specifically warned against. Glutathione is not FDA-approved as a drug in the United States except in specific formulations (e.g., for prevention of platinum chemotherapy neuropathy in some jurisdictions; nebulized forms for cystic fibrosis trials). It is available as an over-the-counter supplement in oral, liposomal, and sublingual forms. IV and nebulized formulations are typically prepared by compounding pharmacies and administered in clinical settings. Intranasal formulations are increasingly available as compounded prescriptions or from reputable peptide suppliers. If you are considering glutathione supplementation, the honest framing is this: glutathione is a real biochemical entity with real physiological roles, and there are specific contexts (acetaminophen overdose, NAFLD, early Parkinson's, cystic fibrosis) where supplementation has coherent evidence of benefit. Beyond those contexts, use is largely empirical — driven by mechanism and by subjective reports of benefit rather than by strong trials. It is generally safe at typical supplement doses, it stacks cleanly with most other health practices, and at worst it is an expensive placebo. At best, in appropriate contexts, it is one of the more scientifically grounded interventions in the longevity and biohacking space.

Also known as: Tauroursodeoxycholic Acid, Tauroursodiol, TURSO, Taurolite, UR-906, Xiong Dan (Traditional Chinese medicine black bear bile), Tauro-UDCA

TUDCA (tauroursodeoxycholic acid) is a hydrophilic bile acid formed by taurine conjugation of ursodeoxycholic acid (UDCA, the active ingredient in the widely-prescribed cholestasis medication Ursodiol). TUDCA occurs naturally in the bile of bears (particularly Asiatic black bears, where it comprises a substantial fraction of total bile acids), which is the source of its centuries-long use in traditional Chinese medicine as the preparation xiong dan (bear bile), where it has been used for liver disease, eye disease, and inflammatory conditions since at least the 7th century Tang dynasty. Modern pharmaceutical manufacturing produces TUDCA synthetically without animal sourcing, eliminating the ethical and conservation concerns associated with bear bile harvesting while providing a consistent and pure active substance. TUDCA has prescription pharmaceutical status in several European countries (Italy, China) for cholestatic liver disease and is widely available as a dietary supplement in the United States and most Western markets for liver support and broader off-label use. Its rising popularity in three distinct user communities — anabolic steroid users seeking hepatic protection during oral cycles, longevity-focused biohackers interested in ER-stress and mitochondrial effects, and patients with neurodegenerative disease attracted by the landmark AMX0035 ALS trial data — has made TUDCA one of the most-discussed bile-acid therapeutics in research-chemical and supplement markets. Structurally, TUDCA is the taurine-conjugated form of UDCA, which is itself the 7β-hydroxy epimer of chenodeoxycholic acid (CDCA). The taurine conjugation converts the hydrophobic primary bile acid into a more hydrophilic and bioavailable molecule, with the practical effect of improved intestinal absorption, reduced bile acid detergent activity (important for the safety profile — hydrophobic bile acids can damage cell membranes), and superior systemic distribution compared to unconjugated UDCA. TUDCA is a primary mammalian bile acid in some species (notably bears) and a minor bile acid in humans, representing <1% of total human bile acid pool under normal circumstances. Following oral administration in humans, TUDCA is absorbed in the small intestine, enters the enterohepatic circulation, and undergoes extensive first-pass hepatic extraction — meaning that most of an orally-administered dose is rapidly concentrated in the liver and biliary tree, providing high hepatic tissue exposure at relatively modest systemic plasma levels. Functionally, TUDCA acts through multiple overlapping mechanisms that distinguish it from simpler hepatoprotective agents. The classical bile-acid function is replacement of more-toxic hydrophobic bile acids with the non-toxic hydrophilic TUDCA, reducing bile-acid-mediated hepatocyte damage in cholestatic conditions — this is the basis for UDCA's and TUDCA's longstanding use for primary biliary cholangitis (previously primary biliary cirrhosis), primary sclerosing cholangitis, and various cholestatic syndromes of pregnancy and genetic origin. Beyond this classical function, TUDCA is now recognized as a chemical chaperone — a small molecule that stabilizes protein folding and reduces endoplasmic reticulum (ER) stress. When cells experience stress that causes misfolded proteins to accumulate in the ER (a common feature of diabetes, neurodegeneration, ischemic injury, and many chronic diseases), the unfolded protein response (UPR) is activated, which can trigger cell death if the stress is prolonged. TUDCA's chemical chaperone activity reduces ER stress, reduces UPR activation, and has been shown in numerous preclinical models to protect cells from ER-stress-induced apoptosis. This mechanism underlies TUDCA's effects in diabetes (protecting pancreatic beta cells from ER-stress-induced dysfunction), Alzheimer's and Parkinson's models (reducing misfolded-protein-induced neuronal death), ALS (protecting motor neurons), retinitis pigmentosa and other retinal degenerative conditions, and a range of other pathologies where ER stress is a pathogenic factor. The clinical evidence base divides into three tiers. Tier 1 (approved/standard of care): cholestatic liver disease — UDCA (the unconjugated form) has standard-of-care status for primary biliary cholangitis (PBC), where it improves liver biochemistry and in some populations reduces progression to liver transplantation. TUDCA is used in similar contexts in European pharmaceutical markets and shows equivalent or superior efficacy to UDCA for some endpoints. Tier 2 (emerging clinical evidence): ALS — the CENTAUR trial (Paganoni et al. 2020, PMID 32905678) evaluated AMX0035, a fixed-dose combination of TUDCA and sodium phenylbutyrate, in ALS patients and demonstrated 25% slower functional decline and significantly improved survival compared to placebo. FDA approval of AMX0035 under the brand name Relyvrio in 2022 represented the first approval of a TUDCA-containing medication for a non-cholestatic indication. (Relyvrio was subsequently withdrawn from the US market in April 2024 after the Phase 3 PHOENIX trial failed to confirm the Phase 2 benefit, producing active controversy about TUDCA's role in ALS.) Additional neurodegenerative disease trials for Parkinson's disease (including the UP-Parkinson's Phase 2 trial) are in progress. Tier 3 (mechanism-driven off-label use): bodybuilding/liver support during oral anabolic cycles, general antioxidant and "liver detox" supplementation, neuroprotection in the absence of disease, metabolic syndrome and insulin resistance support, and broad longevity applications. Tier 3 uses are driven by plausible mechanism and subjective reports rather than by direct clinical trial evidence in those specific contexts. The bodybuilding and anabolic steroid context deserves specific mention because it drives much of the retail supplement-market demand for TUDCA. 17α-alkylated oral anabolic steroids (methylated compounds including oxandrolone, stanozolol, methandrostenolone, oxymetholone, anadrol, and others) are hepatotoxic, producing cholestatic hepatitis and liver enzyme elevations with chronic use. The bodybuilding community has long used UDCA and more recently TUDCA as hepatoprotective agents during oral steroid cycles, with the pharmacological rationale that bile-acid replacement and chemical-chaperone activity protect against cholestatic hepatotoxicity. Anecdotal reports and limited data support this use. Note that TUDCA does NOT reverse or prevent the underlying hepatotoxicity of 17α-alkylated steroids, nor does it allow safe long-term use of hepatotoxic substances — the pharmacologically honest framing is that TUDCA is a harm-reduction adjunct for users who are going to use oral anabolic steroids regardless, not an indication that oral anabolic steroids are safe when TUDCA is co-administered. This entry covers TUDCA's bile-acid biology and chemical chaperone pharmacology, the traditional Chinese medicine history and transition to modern synthesis, the cholestatic liver disease evidence base, the CENTAUR ALS trial and subsequent FDA approval and withdrawal, the emerging Parkinson's disease work, the diabetes and metabolic research, the bodybuilding/steroid-user context with honest framing, practical dosing across indications, the relatively clean safety profile, drug interactions (limited but including cholestyramine and some others), appropriate stacking with milk thistle, NAC, and other hepatoprotective and antioxidant agents, and honest epistemic framing that separates the solid cholestatic-disease evidence from the ALS evidence (itself now uncertain post-PHOENIX) from the broader off-label longevity and general-health claims that remain largely mechanism-driven.

Also known as: N-Acetylcysteine, N-Acetyl-L-Cysteine, Acetylcysteine, Mucomyst, Acetadote, Fluimucil, Parvolex, NALC, L-α-Acetamido-β-mercaptopropionic acid

N-acetylcysteine (NAC) is the acetylated form of the amino acid L-cysteine — a small thiol-containing molecule that serves as a rate-limiting precursor for glutathione (GSH) synthesis and, independently, as a direct antioxidant and mucolytic agent. Discovered in the 1960s as a mucolytic (via its ability to cleave disulfide bonds in mucus glycoproteins) and repurposed in the mid-1970s as the definitive antidote for acetaminophen (paracetamol) overdose, NAC has one of the broadest therapeutic profiles of any thiol-based medication and is on the World Health Organization's List of Essential Medicines. It is available in multiple regulatory categories depending on jurisdiction: prescription (for IV use in acetaminophen overdose and inhalation/nebulization for mucolytic use), over-the-counter (in much of Europe as oral effervescent tablets branded Fluimucil, ACC, Mucomyst), and as a dietary supplement (in the United States, where it has been sold as a supplement for decades despite a contentious 2020 FDA enforcement notice asserting that NAC's status as a drug — approved 1963 — precludes supplement classification under DSHEA; the FDA walked back enforcement in 2022 and supplement sales resumed, though the legal question technically remains unresolved). Structurally, NAC is L-cysteine with an acetyl group on its amine nitrogen — a simple modification that dramatically improves stability (the free thiol of unmodified cysteine oxidizes rapidly), reduces the taste problem (cysteine is intensely unpleasant), and modestly improves oral tolerability. The acetyl group is cleaved by intracellular deacetylases after uptake, releasing free cysteine into the cellular cysteine pool, where it enters the two-step enzymatic synthesis of glutathione: cysteine + glutamate → γ-glutamylcysteine (by γ-glutamylcysteine synthetase, the rate-limiting enzyme) → GSH (by glutathione synthetase, adding glycine). Because cysteine is rate-limiting for GSH synthesis in most tissues — cysteine is the least abundant of the three GSH amino acids in the free amino acid pool, and its intracellular concentration tracks closely with GSH synthesis rate — delivering cysteine via NAC can meaningfully raise tissue GSH in contexts where GSH is depleted. This is the molecular basis for NAC's acetaminophen antidote effect: acetaminophen overdose generates the toxic metabolite N-acetyl-p-benzoquinone imine (NAPQI) faster than hepatic GSH can conjugate it, GSH is consumed, and hepatocyte death follows unless GSH synthesis is urgently restored by providing exogenous cysteine. The clinical use cases for NAC divide into three tiers by strength of evidence. Tier 1 (strong RCT evidence): acetaminophen overdose (IV NAC via the 21-hour Prescott/Smilkstein protocol or the 72-hour oral Smilkstein protocol — mortality reduction from ~5% to <1% when given within 8-10 hours of ingestion); chronic obstructive pulmonary disease exacerbation reduction (BRONCUS trial and subsequent Cochrane reviews showing modest reductions in exacerbation frequency with high-dose oral NAC, 600-1200 mg/day); idiopathic pulmonary fibrosis (mixed results — earlier IFIGENIA trial was positive, later PANTHER-IPF trial was negative for triple therapy but NAC monotherapy remained in the protocol); contrast-induced nephropathy prevention (large meta-analyses show modest benefit, though the ACT trial called the effect into question and modern practice emphasizes hydration more than NAC). Tier 2 (promising but heterogeneous): psychiatric applications including bipolar depression (Berk 2008, 3-month RCT showing significant improvement in depression and functional outcomes versus placebo); obsessive-compulsive disorder and OCD-spectrum disorders like trichotillomania and nail-biting (Grant 2009 trichotillomania RCT positive, subsequent OCD trials mixed); schizophrenia (Berk 2008 negative symptoms improvement; later trials heterogeneous); cocaine, cannabis, and gambling addiction (signal for cannabis and early-abstinence cocaine, weaker for gambling); Alzheimer's and Parkinson's disease (preclinical and small-trial rationale, no definitive evidence); male infertility (Ciftci 2009 showing improved sperm parameters in idiopathic oligoasthenoteratozoospermia); polycystic ovary syndrome (Rizk 2005, Fulghesu 2002 showing improved insulin sensitivity and ovulation). Tier 3 (mechanism-driven but not rigorously tested in humans): generalized "antioxidant supplementation" in healthy individuals, "detox" protocols, alcohol hangover prevention, exercise performance or recovery support, sleep support (NAC is sometimes promoted for sleep, though the evidence is weak), and broad longevity support as a GSH-preserving agent — these uses are empirical and driven primarily by mechanism rather than by direct clinical data in healthy populations. NAC is one of the most-studied thiol therapies in medicine, with over 15,000 PubMed-indexed publications and active investigation across dozens of additional indications including COVID-19 (mostly negative for acute infection, some signal for long COVID symptoms), post-traumatic stress disorder (small trials, promising), autism spectrum disorder (irritability and repetitive behaviors), sickle cell disease, radiation-induced toxicity prevention, and aminoglycoside-induced hearing loss. The combination of low cost (typical oral dose costs pennies per day), favorable safety profile (side effects are almost entirely limited to gastrointestinal upset at high doses and rare anaphylactoid reactions to IV infusion, which are rate-dependent rather than truly allergic), wide availability, and coherent mechanistic rationale has made NAC one of the workhorses of off-label psychiatric and biohacker medicine. This entry covers NAC's glutathione-precursor and direct-antioxidant mechanisms, the pharmacokinetic peculiarities (oral bioavailability is only 4-10% as intact NAC, though effective for raising cysteine pools), the established acetaminophen-overdose and COPD/mucolytic evidence, the psychiatric and addiction medicine literature, the male fertility and PCOS data, practical dosing by indication, the 2020 FDA regulatory episode and its implications, appropriate stacking with other antioxidants and glutathione-pathway nutrients, the relatively narrow but real contraindication set, and the honest framing that distinguishes where NAC has strong evidence (overdose, mucolytic, specific psychiatric conditions) from where it is being taken on faith (general "antioxidant" supplementation in healthy people).

Also known as: ALA, α-Lipoic acid, Alpha lipoic acid, Thioctic acid, R-Lipoic acid, R-ALA, R-(+)-Lipoic acid, S-Lipoic acid, Na-R-ALA, Sodium R-lipoate, Lipoate, 1,2-Dithiolane-3-pentanoic acid

Alpha-lipoic acid (ALA), also known as thioctic acid or 1,2-dithiolane-3-pentanoic acid, is a sulfur-containing eight-carbon fatty acid derivative synthesized endogenously in mitochondria by lipoic acid synthase (LIAS). In its native biological role, ALA serves as an essential cofactor for five critical mitochondrial dehydrogenase enzyme complexes: pyruvate dehydrogenase (the gateway from glycolysis to the citric acid cycle), α-ketoglutarate dehydrogenase (a rate-limiting TCA cycle enzyme), branched-chain α-ketoacid dehydrogenase (metabolizing leucine, isoleucine, and valine), 2-oxoadipate dehydrogenase, and the glycine cleavage system. In all these roles, ALA is covalently attached via an amide bond to a specific lysine residue on a dihydrolipoyl-binding subunit, where it serves as a "swinging arm" that shuttles acyl groups and reducing equivalents between catalytic sites. Loss of lipoic acid synthase function produces a catastrophic inherited metabolic disease; no human can live without endogenous ALA. When taken as a dietary supplement, exogenous ALA does not meaningfully replace or supplement the endogenous enzyme-bound lipoic acid — the biosynthetic pathway is tightly compartmentalized, and supplemental ALA does not become covalently attached to dehydrogenase complexes. Instead, supplemental ALA exerts its biological effects through a different mechanism: it exists transiently in the plasma and cytoplasm as a free molecule and redox couple with dihydrolipoic acid (DHLA), where it functions as one of the most versatile antioxidants known in human biology. Unlike most antioxidants that are restricted to either water-soluble or lipid-soluble compartments, ALA and DHLA are amphipathic — they function effectively in both aqueous cytoplasm and lipid membranes, enabling them to quench free radicals across the cellular landscape. Lester Packer's seminal review (PMID 8974124) designated ALA a "universal antioxidant" in recognition of this dual-phase activity and its capacity to regenerate oxidized forms of vitamin C, vitamin E, glutathione, and CoQ10 back to their active reduced states. This regenerative function makes ALA a keystone in the network of cellular antioxidant recycling. The strongest clinical evidence for supplemental ALA is in diabetic neuropathy, where Germany has licensed ALA at 600 mg/day since the 1960s based on the ALADIN series of randomized trials (PMIDs 7589950, 10391387), the SYDNEY 2 trial (PMID 17140036), and the four-year NATHAN 1 study (PMID 21953615). These trials established that 600 mg/day of oral ALA meaningfully reduces neuropathic symptoms (pain, burning, paresthesias, numbness) and improves nerve conduction in patients with type 1 and type 2 diabetes. The mechanism appears to combine direct antioxidant protection of vulnerable peripheral nerves, improved microvascular perfusion via nitric oxide enhancement, modulation of polyol and hexosamine pathway damage from hyperglycemia, and genuine insulin-sensitizing effects on glucose disposal. Beyond neuropathy, ALA has been investigated for insulin resistance and metabolic syndrome, non-alcoholic fatty liver disease, mitochondrial disorders, stroke recovery, burning mouth syndrome, and weight management — with evidence quality and effect sizes varying widely. ALA also has a small but important role in heavy metal chelation, particularly mercury and arsenic. The dithiol structure of dihydrolipoic acid (DHLA, the reduced form of ALA) can bind soft metal cations. Andrew Cutler's protocols for mercury detoxification popularized ALA as a chelator among biohackers; while the mainstream chelation medical community uses DMSA or DMPS as first-line agents, ALA has an established but more peripheral role. The protocol logic depends on careful dosing schedules that respect the short plasma half-life (30-60 minutes) of ALA to avoid mobilizing mercury from stable deposits faster than the body can excrete it. For BodyHackGuide readers, ALA represents an antioxidant with legitimate clinical evidence in specific indications, meaningful insulin-sensitizing effects, and a niche role in mitochondrial support — but it is not a "clean" supplement in the sense that vitamin D or magnesium are. ALA requires attention to isomer selection (R-ALA is the natural form with better bioavailability; S-ALA is the synthetic enantiomer present in racemic commercial products), absorption tuning (empty stomach is important), biotin competition (chronic high-dose ALA can induce functional biotin deficiency), hypoglycemia risk in diabetics taking insulin or sulfonylureas, and the unfortunate reality that most over-the-counter ALA products are racemic rather than pure R-ALA. This page covers the biochemistry, the diabetic neuropathy evidence, the chelation debate, stacking with glutathione-system and mitochondrial nutrients, and practical dosing considerations.

Also known as: Epitalon

Epithalon (also spelled Epitalon, sequence Ala-Glu-Asp-Gly / AEDG) is a synthetic tetrapeptide designed by Prof. Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology in the 1980s as a short-chain analog of epithalamin, a peptide extract of bovine pineal gland. It is the most-studied "longevity peptide" in the Russian peer-reviewed literature, with over 30 years of published work on telomerase activation, telomere lengthening, melatonin restoration, and life-span extension in rodents. The core biology is three-fold: Telomerase activation in somatic cells — Khavinson and Smirnova showed that 10 ng/mL AEDG increased hTERT expression and telomerase activity in human somatic fibroblasts, extending proliferative capacity by ~42% over the Hayflick limit (Khavinson et al., 2003, Bull Exp Biol Med). Restoration of pineal melatonin secretion — In aged rats and in elderly humans, epithalon restored the nocturnal melatonin peak that declines with pineal calcification, improving circadian amplitude and sleep architecture (Anisimov et al., 2003). Direct chromatin binding (epigenetic) — NMR and X-ray studies demonstrate that AEDG binds the major groove of DNA at specific sequences, modulating transcription of interferon-γ, hTERT, and cell-cycle regulators (Fedoreyeva et al., 2011). Critical evidence-quality caveat: Unlike BPC-157 or the GLP-1 agonists, the human clinical evidence for Epithalon is almost entirely from Russian-language publications from a single research consortium (Khavinson / Anisimov / Korkushko). Western replication is minimal. The rodent data are compelling — a ~30% median life-span extension in female mice (Anisimov et al., 2003) — but translating this to human longevity remains hypothesis rather than demonstrated fact. Epithalon is used in biohacking communities for: Sleep consolidation in adults over 40 (melatonin restoration) Telomere preservation as part of a longevity stack Circadian rhythm repair after shift-work or jet lag Adjunct in age-related immunosenescence It is delivered by subcutaneous injection, typically 5-10 mg/day for 10-20 consecutive days, followed by a 3-6 month washout. This intermittent pulsing is intentional — Khavinson's protocols were always short-cycle, never continuous — and is a key safety feature in the absence of long-term continuous-dosing data.

Also known as: Copper Peptide, GHK Copper

GHK-Cu (copper peptide, glycyl-L-histidyl-L-lysine:copper(II)) is a naturally occurring tripeptide-copper complex with the amino acid sequence Gly-His-Lys chelated to a copper(II) ion. It has a molecular weight of 403.93 Da and a CAS number of 49557-75-7. GHK-Cu was first identified in human plasma by Pickart and Thaler in 1973, who observed that plasma from young individuals (age 20-25) stimulated hepatocyte protein synthesis more effectively than plasma from older donors (age 60-80), and isolated GHK as the active factor (PMID: 25815018). GHK-Cu is present in human plasma at approximately 200 ng/mL in young adults, with concentrations declining significantly with age — dropping to approximately 80 ng/mL by age 60. This age-related decline in GHK-Cu has been proposed as a contributing factor to reduced tissue repair capacity, skin thinning, and slower wound healing observed in aging populations (PMID: 25815018). A landmark gene expression study by Pickart et al. (2012) using the Broad Institute Connectivity Map demonstrated that GHK-Cu modulates the expression of over 4,000 human genes, with a net effect that shifts gene expression patterns from a diseased or aged state toward a healthier, younger profile. Key upregulated gene categories include collagen synthesis, antioxidant defense, DNA repair, and anti-inflammatory pathways. Key downregulated categories include pro-inflammatory cytokines, fibrinogen production, and metastasis-related genes (PMID: 22585403). In wound healing research, GHK-Cu has demonstrated strong efficacy across multiple models. Topical GHK-Cu accelerates wound contraction, stimulates angiogenesis, and increases collagen deposition in dermal wounds. It activates fibroblasts and attracts immune cells including macrophages and mast cells to the wound site, coordinating the inflammatory-to-proliferative phase transition (PMID: 28500824). In aged skin models, GHK-Cu restored dermal thickness and improved skin elasticity through stimulation of collagen I and III synthesis and inhibition of excessive matrix metalloproteinase (MMP) activity (PMID: 24508067). GHK-Cu is widely available as a cosmetic ingredient in serums, creams, and dermal patches. It is approved for cosmetic use in the United States and European Union. Beyond topical application, GHK-Cu is also administered via subcutaneous injection in the biohacking community for systemic anti-aging and recovery purposes, though this route lacks formal clinical validation. The peptide complex is relatively stable when lyophilized and should be stored at 2-8 degrees Celsius for topical formulations or at -20 degrees Celsius for injectable-grade lyophilized powder. GHK-Cu has an extremely short plasma half-life of approximately 30 minutes, but its tissue-level effects persist for hours to days due to gene expression changes it initiates upon cellular uptake.

Also known as: HNG

Humanin is a 24-amino-acid peptide (MAPRGFSCLLLLTSEIDLPVKRRA) encoded within the mitochondrial 16S ribosomal RNA gene and translated from a short open reading frame that was not recognized as biologically active until 2001, when Hashimoto and colleagues identified it in a screen for factors that protect neurons from Alzheimer's disease-associated toxicity (Hashimoto et al., 2001). The discovery was methodologically elegant: using a cDNA library from the occipital lobe of a patient who had died of Alzheimer's disease but whose specific brain region had remained clinically unaffected, they identified a peptide that protected cultured neurons from beta-amyloid toxicity, and traced its origin back to an unexpected locus in the mitochondrial genome. The finding launched an entire field — mitochondrial-derived peptides or MDPs — that now includes humanin, MOTS-c, SHLP1 through SHLP6, and related small peptides encoded within mitochondrial DNA that have systemic endocrine and autocrine signaling functions. Humanin itself has since been shown to protect cells from a range of stressors including beta-amyloid toxicity, Bax-induced apoptosis, oxidative stress, hypoxia-reoxygenation, and serum starvation (Guo et al., 2003; Tajima et al., 2002; Zhai et al., 2005). It also has metabolic effects including improved insulin sensitivity, enhanced glucose disposal, and protection against atherosclerosis in mouse models (Muzumdar et al., 2009). Plasma humanin concentrations are relatively high in young humans and decline with age, which has prompted speculation that restoring humanin to youthful levels could be a longevity intervention (Cobb et al., 2016). The practical reality of humanin as a research peptide is more complicated than the mechanism summary suggests. The endogenous peptide has a short circulating half-life (minutes), is rapidly cleared, and does not cross the blood-brain barrier efficiently in its native form. Synthetic analogs with substitutions to improve stability and potency have been developed — the most studied is HNG (humanin S14G), which is roughly 1000-fold more potent than wild-type humanin in several assays and has been used in most of the preclinical therapeutic work (Hashimoto et al., 2001; Yen et al., 2013). Other analogs with different substitution patterns (HNA, [Gly14]-HN, colivelin which fuses humanin with the activity-dependent neurotrophic factor peptide) have been generated for various experimental purposes. What is being sold as "humanin" by research-chemical peptide vendors is typically the wild-type 24-amino-acid sequence, not HNG, and the wild-type peptide has substantially less in vivo activity than the published HNG data would suggest. Consumers reading mechanism summaries that cite HNG mouse studies and then buying wild-type humanin are effectively purchasing a different compound than the one described in the research. Humanin has not been developed as an FDA-approved drug and has no human trial data establishing a therapeutic dose or efficacy profile. It remains an investigational peptide with strong mechanistic rationale, extensive preclinical evidence, and no clinical validation. This entry covers what the peptide actually does, how it signals through its receptor complex, what the animal data show in models of aging, neurodegeneration, diabetes, and cardiovascular disease, where the evidence is strongest and where it is thin, and what realistic use looks like for someone interested in mitochondrial-derived peptide biology. If the goal is neuroprotection or metabolic improvement, FDA-approved interventions (lifestyle, approved medications) should be fully explored first. If the goal is participating in the cutting edge of mitochondrial peptide research as a self-experimenter, this page is the most honest summary available of what the evidence does and does not support.

Also known as: MOTS-c

MOTS-c (Mitochondrial ORF of the Twelve S rRNA type-c) is a 16-amino-acid mitochondrial-derived peptide — a member of a recently discovered class of small peptides encoded in mitochondrial DNA rather than nuclear DNA. It was first characterized and named by Lee et al. in 2015 at Pinchas Cohen's laboratory at USC, representing a paradigm shift in mitochondrial biology: the mitochondria are not merely recipients of nuclear regulatory signals, they produce their own signaling peptides that act both locally and systemically on metabolism. The MOTS-c sequence (M-R-W-Q-E-M-G-Y-I-F-Y-P-R-K-L-R-H) is encoded in the 12S rRNA region of mitochondrial DNA. Under metabolic stress conditions — fasting, caloric restriction, exercise — mitochondria translate and release MOTS-c into circulation, where it acts as an exercise-mimetic and metabolic regulator with primary effects on skeletal muscle, adipose tissue, and liver. The core pharmacologic mechanism is AMP-activated protein kinase (AMPK) agonism, the same metabolic master-switch targeted by metformin, exercise, and caloric restriction. AMPK activation drives: GLUT4 translocation to the muscle cell membrane → increased glucose uptake Fatty acid oxidation upregulation via ACC phosphorylation Mitochondrial biogenesis via PGC-1α pathway Inhibition of de novo lipogenesis and gluconeogenesis Improved insulin sensitivity at multiple tissue sites Preclinical studies document striking effects: MOTS-c treatment in diet-induced obese mice produces weight loss, restored insulin sensitivity, normalized glucose tolerance, and enhanced exercise capacity (Lee 2015; Reynolds 2021). In aging studies, MOTS-c administration to aged mice restores exercise performance to that of young animals and reverses age-related metabolic dysfunction (Reynolds 2021). Importantly, endogenous MOTS-c levels decline with aging and are suppressed in metabolic disease states. This has generated the hypothesis that declining MDP production is a causal contributor to age-related metabolic decline — positioning MOTS-c replacement as a potential longevity intervention analogous to hormone replacement, though the evidence base is still primarily preclinical. MOTS-c is not FDA-approved for any indication. Research-chemical use for metabolic tuning, athletic performance, and longevity purposes is emerging but limited; typical protocols use 5-10 mg SC 2-3 times weekly. Human pilot data is scarce; most efficacy inferences come from animal models and mechanistic plausibility.

Also known as: AED

Cartalax is a short synthetic peptide developed in Russia by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology, positioned as a "cartilage bioregulator" intended to support chondrocyte function, cartilage matrix synthesis, and joint tissue resilience in age-related osteoarthritis, post-traumatic joint disease, and intervertebral disc degeneration. It is usually described in Khavinson-family publications as the tetrapeptide Ala-Glu-Asp-Leu (AEDL), sometimes written H-Ala-Glu-Asp-Leu-OH or A-E-D-L, though the literature also references slight sequence variants in early publications. Cartalax sits alongside Pinealon, Thymogen, Vilon, Epitalon, Livagen, Bronchogen, and Cardiogen within the Khavinson short-peptide bioregulator family, and is the defined-sequence counterpart to a polypeptide preparation called Sygumir (in some marketing) or cartilage-derived polypeptide complexes from Khavinson's original extract programme. Outside Russia, Cartalax is not registered as a drug, not reviewed by FDA, EMA, or PMDA, and not in any WADA category — though the WADA S0 non-approved substances clause arguably applies for competitive athletes. There are no phase II or phase III RCTs in PubMed or ClinicalTrials.gov, and Cartalax does not appear in OARSI, ACR, or EULAR osteoarthritis guidelines. Published Russian work comprises in vitro chondrocyte culture studies, rodent osteoarthritis model experiments, and small uncontrolled observational series in elderly patients with knee, hip, and spinal osteoarthritis (Khavinson et al., 2011; Chalisova et al., 2014; Anisimov et al., 2010). The central claim for Cartalax is the standard Khavinson short-peptide model applied to cartilage tissue: passive membrane permeation into chondrocytes, nuclear import, sequence-selective chromatin modulation, and preferential upregulation of chondrocyte survival, matrix synthesis (type II collagen, aggrecan, hyaluronic acid), and anti-catabolic programmes (downregulation of MMPs, ADAMTS). The tissue-specificity claim — that AEDL selectively targets cartilage rather than other connective tissue — is asserted but not supported by modern biodistribution, structural biology, or transcriptomics. The hypothesis is internally consistent within the Khavinson programme; it is substantially less validated than the pharmacology of evidence-graded osteoarthritis therapy. BodyHackGuide covers Cartalax because it is sold online in post-Soviet supplement channels (typically 20 mg oral capsules) and appears in longevity-stack discussions alongside joint-support adjuncts. We describe what is known, what is claimed, and what is missing — and we steer readers seeking evidence-graded joint and cartilage support toward interventions with better replication: weight management (single most impactful intervention for knee OA), structured exercise and physical therapy, NSAIDs where appropriate for symptomatic relief, intraarticular corticosteroid or hyaluronic acid injection, topical NSAIDs, Curcumin and Boswellia for modest anti-inflammatory benefit, collagen peptides and undenatured type II collagen (UC-II) with mixed but some positive evidence, BPC-157 and TB-500 as experimental peptide options with more mechanism data than Cartalax, and surgical intervention (arthroscopy, joint replacement) where indicated. Cartalax is a plausible hypothesis. It is not, in 2026, an evidence-graded cartilage therapy.

Also known as: Vessel peptide

Vesugen is a short synthetic peptide developed within Vladimir Khavinson's laboratory at the Saint Petersburg Institute of Bioregulation and Gerontology and marketed in Russia as an oral capsule for vascular and endothelial system support. The reported sequence is a tripeptide, H-Lys-Glu-Asp-OH (KED), though some sources list it with a C-terminal amide. Within the Khavinson short-peptide bioregulator catalog — Epitalon, Thymogen, Pinealon, Vilon, Livagen, Bronchogen, Cardiogen, Cartalax, Chonluten, Ovagen, Testagen, and Prostamax — Vesugen occupies the vascular tissue niche. Cardiogen is the companion cardiac peptide; Vesugen is marketed specifically for the vessel wall rather than the myocardium. Like the rest of the Khavinson capsule line, commercial Vesugen is a 20 milligram nominal capsule containing approximately 2 to 4 milligrams of synthetic peptide dispersed in milk-protein and starch excipients. The 20 mg on the bottle refers to total powder weight, not peptide dose. This matters because users reading vendor sites sometimes assume they are getting a much larger peptide quantity than is actually present. Vesugen is sold as an over-the-counter supplement in Russia and Eastern Europe and as a research compound in other markets. It is not a registered pharmaceutical in the United States, the European Union, the United Kingdom, Canada, or Australia. It is not FDA-approved for any indication. It has not undergone phase 3 Western randomized controlled trials. All human clinical evidence for Vesugen is from small single-center Russian-language observations and reviews from Khavinson's group and affiliated collaborators, with limited independent replication. Readers evaluating Vesugen for their own cardiovascular health are comparing a niche Russian bioregulator to mainstream cardiology pharmacology — statins, PCSK9 inhibitors, ezetimibe, antihypertensives, antiplatelet agents, SGLT2 inhibitors, and GLP-1 agonists — where the evidence gap is enormous. BodyHackGuide treats Vesugen honestly rather than promotionally. If a reader is researching vascular bioregulators, the goal of this page is to explain what Vesugen is, what the Khavinson framework claims, where the evidence is thin, how it would theoretically fit into a serious cardiovascular prevention plan, what safer and better-evidenced alternatives exist, and which contraindications and interactions matter. The framing throughout is that Vesugen is at best a low-priority adjunct in a well-constructed vascular health plan, and at worst an unnecessary purchase that displaces attention from the evidence-based interventions that actually move cardiovascular outcomes. A reader worried about vascular aging, endothelial dysfunction, hypertension, hyperlipidemia, atherosclerosis, stroke risk, or peripheral arterial disease should be working with a cardiologist or internist on statins, antihypertensives, antiplatelets, and lifestyle — not relying on a Russian tripeptide. The Khavinson framework for Vesugen follows the same three-stage mechanistic story that applies to the whole short-peptide line. Stage one is absorption from the gut and passive membrane crossing into target tissue cells. Stage two is passive nuclear import, with short peptides entering nuclei and reaching chromatin. Stage three is sequence-selective binding to DNA regulatory regions associated with vascular and endothelial gene programs. In Vesugen's case, the target tissue is claimed to be vascular smooth muscle and endothelium, with effects on endothelial nitric oxide synthase (eNOS), endothelial growth factors, pro- and anti-inflammatory gene regulation, and the chromatin state of aging endothelial cells. The claim is that cycled oral dosing can partially reset the endothelial transcriptional program back toward a younger pattern, improving nitric oxide bioavailability, vessel relaxation, and resistance to atherogenic lipid deposition. That framework is elegant but not robustly validated outside Khavinson's laboratory. The biochemical basis for short-peptide tissue selectivity remains contested in mainstream molecular biology. The pharmacokinetic claim — that orally delivered tripeptides survive gastric proteolysis, cross the gut wall intact, and reach vascular tissue nuclei at concentrations relevant to gene regulation — is not independently established at the quantitative level required to support the clinical claims. A reader should understand that the mechanism-of-action story is a theoretical model rather than a settled body of biochemistry. The main demographic buying Vesugen is men and women in their forties through sixties who are worried about vascular aging. Typical concerns include: modestly elevated blood pressure, borderline lipid panels, family history of stroke or myocardial infarction, peripheral cool extremities, varicose veins or spider veins, concerns about erectile or sexual vascular function, mild endothelial dysfunction markers, concerns about dementia-vascular pathology overlap, and generalized "longevity" interests. Each of those concerns has an evidence-based workup and treatment pathway that vastly outstrips what Vesugen can offer. A reader with one or more of those concerns should be working through that pathway — not treating a Russian capsule as a shortcut. Vesugen is most commonly used in a 10-days-on cycle followed by a 60 to 90 day washout, per the Khavinson cycling convention. Each dose is 1 or 2 capsules on an empty morning stomach. Cycles are typically repeated two to four times per year, often paired with Cardiogen (for those with both cardiac and vascular concerns), Epitalon (for generalized longevity framing), Pinealon (for cognitive-vascular overlap), or Thymogen (immune support). Reconstitution is not required for the oral capsule form. Injectable Vesugen is a research-chemical formulation rather than the commercial product and is not recommended for users without research-chemical experience and clinical oversight. Safety observation in the published Khavinson work has been consistently reassuring at the oral doses used, but the trial base is small and short. This page treats "well tolerated" as a provisional claim rather than a conclusion. The theoretical safety concerns specific to Vesugen include drug interactions with antihypertensives and antiplatelets (where additive effects are possible but uncharacterized), interactions with statins (where no direct interaction is known but monitoring is reasonable), and interactions with anticoagulants (where peptide effects on coagulation and platelet function are not characterized in published data). A reader on these classes of medications should consult their cardiologist before starting Vesugen — not for regulatory reasons but for coherent integration of any observed effects with their existing therapy. The honest positioning on this page: Vesugen is a niche adjunct to a real cardiovascular prevention plan, and the plan matters more than the peptide. The plan is lifestyle (aerobic training, resistance training, diet, weight, sleep, stress), evidence-based pharmacology (statins, antihypertensives, antiplatelets, SGLT2 inhibitors, GLP-1 agonists where indicated), preventive screening (lipid panel, blood pressure monitoring, CAC score or carotid imaging in select cases, diabetes screening, kidney function), and clinical relationship (primary care, cardiology when risk is elevated). Vesugen cycling can be layered onto that plan for users who want to experiment with the Khavinson framework. It cannot replace that plan.

Also known as: Cardiac peptide

Cardiogen is a short synthetic peptide developed in Russia by Vladimir Khavinson and his collaborators at the St. Petersburg Institute of Bioregulation and Gerontology, positioned as a "myocardial bioregulator" intended to support cardiomyocyte function, vascular endothelium, and cardiac tissue resilience in age-related cardiovascular decline, post-infarction recovery, and chronic heart failure. It is usually described in Khavinson-family publications as the tetrapeptide Ala-Glu-Asp-Arg (AEDR), sometimes rendered H-Ala-Glu-Asp-Arg-OH or A-E-D-R, and sits alongside Pinealon, Thymogen, Vilon, Epitalon, Livagen, and Bronchogen within the Khavinson short-peptide bioregulator family. Cardiogen is the synthetic defined-sequence counterpart to a polypeptide product called Chelohart (or Korteksin for the brain-targeted version), which is prepared from bovine cardiac tissue extract — mirroring the extract-plus-defined-sequence pattern Khavinson's group applies across the bioregulator programme. Outside Russia, Cardiogen is not registered as a drug, not reviewed by FDA, EMA, or PMDA, and not listed on WADA's Prohibited List — though the WADA S0 catch-all for "non-approved substances" arguably covers any unregistered peptide for competitive athletes. There are no phase II or phase III randomised trials indexed in PubMed or ClinicalTrials.gov, and Cardiogen does not appear in ACC/AHA, ESC, or NICE guidelines for ischaemic heart disease, heart failure, or cardiac aging. The published Russian work comprises in vitro cardiomyocyte culture experiments, small rodent studies of induced cardiac injury, and uncontrolled observational case series in elderly patients with chronic cardiovascular disease (Khavinson et al., 2011; Chalisova et al., 2014; Anisimov et al., 2010). The central claim for Cardiogen is the standard Khavinson short-peptide model applied to cardiac tissue: passive membrane permeation through the cardiomyocyte sarcolemma, nuclear import, and sequence-selective chromatin modulation producing preferential up-regulation of cardiomyocyte-survival, mitochondrial-biogenesis, and regeneration programmes. Tissue-specific targeting toward the heart — rather than liver, brain, or thymus — is asserted but not supported by structural biology, modern biodistribution, or contemporary transcriptomic characterisation of cardiac tissue after AEDR exposure. The hypothesis is internally consistent within the Khavinson framework; it is substantially less validated than the pharmacology of even modestly-studied cardiac therapies. BodyHackGuide covers Cardiogen because it is sold online in post-Soviet supplement channels (typically 20 mg oral capsules containing an undisclosed amount of actual peptide) and appears frequently in longevity-stack discussions framed as a cardiac-support bioregulator. We describe what is known, what is claimed, and what is missing — and we steer readers seeking evidence-graded cardiovascular protection toward interventions with overwhelming replication: blood-pressure control, LDL-cholesterol reduction via statins and PCSK9 inhibitors, SGLT2 inhibitors for heart failure and diabetic cardiomyopathy, GLP-1 agonists for cardiometabolic risk, anticoagulation where indicated, and aerobic exercise as the single most important lifestyle variable in cardiac aging. Cardiogen is a plausible hypothesis. It is not, in 2026, a cardiovascular therapy.

Also known as: Ala-Glu-Asp-Gly, Cardiac Bioregulator, Cortexin (related), Khavinson Cardiac Peptide

Cortagen is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) from the Khavinson bioregulator family developed at the St. Petersburg Institute of Bioregulation and Gerontology. It is organ-targeted to cardiac and coronary tissue, studied for cardiac function preservation and coronary artery health in aging and post-ischemic models. Like other Khavinson bioregulators (Pinealon, Bronchogen, Cartalax, Epithalon), Cortagen is proposed to act via direct gene-regulatory mechanisms in target tissue rather than classical receptor-ligand signaling. Russian clinical literature includes use in elderly patients with cardiovascular disease and post-myocardial infarction recovery. It is distinct from the cortex-targeting Khavinson peptide Cortexin.

Also known as: Lys-Glu

Vilon is the simplest member of Vladimir Khavinson's short-peptide bioregulator catalog — a dipeptide of lysine and glutamic acid (H-Lys-Glu-OH, abbreviated KE). Developed at the Saint Petersburg Institute of Bioregulation and Gerontology in the late 1990s as a synthetic follow-on to the first-generation thymus polypeptide extracts (Thymalin, Thymogen), Vilon was positioned as a minimal-sequence immune and thymic bioregulator. Within the broader Khavinson catalog — Epitalon, Thymogen, Pinealon, Livagen, Bronchogen, Cardiogen, Cartalax, Chonluten, Ovagen, Testagen, Prostamax, and Vesugen — Vilon occupies a foundational position. It is the first compound in the short-peptide line and the one most consistently cited across Khavinson's theoretical framework because its extreme structural simplicity makes it the cleanest test case for his sequence-selective DNA binding and tissue-specific gene modulation claims. Commercial Vilon is sold as an oral capsule in Russia and Eastern European markets. The standard 20 mg nominal capsule contains approximately 2 to 4 mg of synthetic peptide dispersed in milk-protein and starch excipients — the same formulation strategy used across the Khavinson capsule line. It is also available in some markets as a subcutaneous lyophilized peptide for injection. Vilon is not a registered pharmaceutical in the United States, the European Union, the United Kingdom, Canada, or Australia. It is not FDA-approved for any indication. It is sold as a research chemical or as an over-the-counter supplement depending on jurisdiction. The Khavinson literature positions Vilon as a broad-spectrum immune modulator with reported effects on thymus-derived lymphocyte maturation, peripheral T-cell subset balance, natural killer cell activity, and age-related immune decline. Because lysine and glutamate are both charged amino acids (Lys positive, Glu negative) and because the dipeptide has only two peptide-bond-linked residues, Khavinson has argued that Vilon represents the minimum recognizable unit of his tissue-selective DNA binding model. The theoretical claim is that a two-residue ligand can still make enough electrostatic and hydrogen-bonding contacts with specific DNA sequences to influence transcription at particular promoters — a stronger assertion than most Western molecular biology would comfortably accept, but foundational to the Khavinson framework. BodyHackGuide treats Vilon honestly rather than promotionally. All human clinical evidence for Vilon is from small observational studies from Khavinson's group and a limited set of Russian and Eastern European collaborators. Independent Western replication is sparse. The claim that a synthetic dipeptide of this simplicity produces reproducible, tissue-specific, clinically meaningful effects on human immune function is not established by the evidence standards that Western regulators require for therapeutic approval. Readers evaluating Vilon for immune support should compare it to vaccination, evidence-based chronic disease management (diabetes, obesity, hypertension control, all of which modulate immune function), sleep tuning, exercise, and micronutrient sufficiency (vitamin D, zinc, selenium) — all of which have substantially stronger evidence for supporting immune outcomes than any Khavinson peptide. The main demographic buying Vilon is older adults concerned about age-related immune decline (immunosenescence). The biology of immunosenescence is real and well characterized — thymic involution over the lifespan, reduced naive T-cell output, diminished T-cell receptor repertoire, impaired vaccine responses, reduced NK cell cytotoxicity, increased susceptibility to infection, and increased incidence of cancer with age. The question is whether a synthetic dipeptide cycled twice a year can produce clinically meaningful mitigation of those changes. The Khavinson framework argues yes; mainstream immunology reserves judgment. A reader considering Vilon for age-related immune concerns should layer it onto a solid foundation — annual influenza vaccination, recommended COVID-19 boosters, pneumococcal vaccination at appropriate ages, shingles vaccination, routine cancer screening, lifestyle tuning — rather than relying on it as a primary immune strategy. A secondary demographic is users interested in Khavinson's broader anti-aging framework. Vilon is often cycled alongside Epitalon in anti-aging stacks, with the theoretical justification that Epitalon acts on the pineal gland (circadian, telomerase) while Vilon acts on the thymus (immune, T-cell). The paired-axis framing is central to Khavinson's "pineal-thymic" model of aging, in which declining pineal and thymic function are proposed as interlocked drivers of systemic aging. Whether that framework is accurate at the level of clinical intervention is an open question; the framework itself is coherent at the level of observation that both organs undergo age-related involution. Vilon is most commonly cycled as 1 or 2 oral capsules daily on an empty stomach for 10 consecutive days, followed by a 60 to 90 day washout, with 2 to 4 cycles per year. Injectable Vilon follows a similar pattern at doses of 50 to 200 mcg subcutaneously daily during an active cycle. Users frequently layer Vilon with Thymogen for immune goals, with Epitalon for anti-aging goals, or with Pinealon for cognitive-immune overlap. Safety observation in the published Khavinson work has been consistently reassuring at the oral doses used. Because Vilon is structurally very simple (a dipeptide, 275 Da molecular weight), and because lysine and glutamate are standard dietary amino acids, acute toxicity at the microgram-to-milligram doses used is essentially zero. The tolerability is similar to taking a very small amount of a dipeptide that already occurs in partial proteolytic digests of any dietary protein. Theoretical concerns specific to Vilon include hypothetical unintended immune activation (not observed in practice but possible), hypothetical interaction with immunosuppressive therapy (not characterized in published data), and the general concern applicable to all Khavinson peptides that the published evidence base is too small to detect rare serious adverse events. A reader on active immunosuppressive therapy (post-transplant, active autoimmune disease on biologics, active cancer therapy) should not initiate Vilon without their specialist's input. The honest positioning on this page: Vilon is the simplest and longest-studied Khavinson peptide, with a modest amount of Russian clinical observational data supporting tolerability and suggesting weak-to-moderate immune-modulatory effects. It is not a replacement for vaccination, evidence-based lifestyle management of chronic disease, or disease-specific immune therapies where indicated. It can be considered as an experimental adjunct for users who want to explore the Khavinson bioregulator framework with the minimum-complexity reference peptide.

Also known as: EDR

Pinealon is a synthetic tripeptide — glutamyl-aspartyl-arginine (Glu-Asp-Arg, or EDR) — developed by the St Petersburg Institute of Bioregulation and Gerontology (IBG) under the leadership of Professor Vladimir Khavinson, the dominant figure in what is collectively known as the "Russian short-peptide bioregulator" school of research. Pinealon was designed as a peptide analog of signaling molecules found in natural extracts of the pineal gland, specifically a class of bioactive compounds that Khavinson's group began isolating and characterizing in the late 1980s as "cytomedins" — short peptides extracted from specific animal tissues and claimed to carry tissue-specific regulatory signals back to the corresponding tissue type. The Khavinson framework is as follows: the pineal gland, like other endocrine and parenchymal organs, contains short regulatory peptides that are involved in cell differentiation, gene expression regulation, and tissue homeostasis. When these natural peptides are purified, sequenced, and synthetic analogs are produced (the short-peptide analogs being the most studied), the synthetic peptides retain the ability to influence the same tissue from which they were derived. Pinealon, as the pineal-derived tripeptide bioregulator, is claimed to act on neural tissue — particularly the brain — to support neuroprotection, cognitive function, circadian regulation, and protection against age-related neurodegeneration. A substantial body of Russian-language clinical and preclinical literature supports these claims, going back to the 1990s and continuing through 2026. The work has been led by Khavinson and his collaborators at the Mechnikov North-Western State Medical University in St Petersburg, published in Russian medical journals (Uspekhi Gerontologii, Bulletin of Experimental Biology and Medicine) and selected Western journals (Neuroendocrinology Letters, Biogerontology). Outside Russia, Pinealon is part of a broader group of short-peptide bioregulators that includes Epitalon, Thymogen, Thymalin, Vilon, Livagen, and others — each claimed to be organ-specific based on the source tissue of the original natural peptide extract. The Western biomedical community has given Khavinson's work a mixed reception. On the positive side, the theoretical framework — that short peptides could function as tissue-specific gene-expression modulators — is scientifically coherent, and a subset of the claims (particularly around Epitalon and telomere biology) has attracted genuine interest and some independent replication. On the skeptical side, the clinical datasets are predominantly Russian, the independent replication of the most dramatic outcomes is thin, the peptides have never been through standard Western regulatory approval processes, and the commercial availability in Russia through the "Cytogen" brand (Cytomed) and various gerontology clinics has driven a significant body-hacking export market without corresponding Western clinical validation. This entry takes the honest position that Pinealon — and the broader Russian short-peptide bioregulator category — represents a plausible mechanism of action with real Russian clinical use, limited Western replication, and a research-grade user experience outside Russia. It is not FDA-approved, not widely available through Western prescription pharmacies, and carries the full research-chemical status in most Western jurisdictions. Users engaging with Pinealon are effectively trusting Khavinson's lab and its affiliated clinical collaborators, without the standard Western regulatory and replication infrastructure. For readers exploring the Khavinson peptide space, see also Epitalon, Thymogen, Cartalax, Vilon, and related entries. For comparison with other short-peptide neuroprotective compounds, see Cerebrolysin (a larger neuropeptide preparation), Semax (Russian ACTH-derived peptide), and Selank.

Also known as: Hepatic peptide

Livagen is a short synthetic peptide developed in Russia by Vladimir Khavinson and his collaborators at the St. Petersburg Institute of Bioregulation and Gerontology, positioned as a "liver bioregulator" intended to normalise age-related and stress-related changes in hepatic tissue. It is usually described in Khavinson-family publications as the tetrapeptide Lys-Glu-Asp-Ala (KEDA), sometimes written as H-Lys-Glu-Asp-Ala-OH or K-E-D-A, and is one of the shortest members of the large peptide-bioregulator family that also includes Epitalon (Ala-Glu-Asp-Gly), Pinealon (Glu-Asp-Arg), Vilon (Lys-Glu), and Thymogen (Glu-Trp). Within that framework, Livagen is the "sibling" peptide to a longer polypeptide preparation called Stamakort/Cortex peptide — which is a porcine liver extract — and is sold in the post-Soviet supplement channel as a dietary capsule alongside the other Khavinson tetrapeptides. Outside Russia and a small number of former-Soviet-state pharmacology journals, Livagen is not a registered drug, not a dietary ingredient reviewed by FDA, EMA or any major English-language regulator, and not a member of the WADA Prohibited List. There are no phase II or phase III randomised trials for Livagen indexed in PubMed or on ClinicalTrials.gov. The published Russian work — most of it co-authored by Khavinson and published in Bulletin of Experimental Biology and Medicine between 2002 and 2015 — describes in vitro chromatin effects and small rodent studies showing modulation of hepatic gene expression, hepatocyte proliferation markers, and restoration of age-related changes in liver morphology (Khavinson et al., 2003; Khavinson and Malinin, 2005; Anisimov et al., 2010). The central therapeutic claim Khavinson's group makes for Livagen is that the Lys-Glu-Asp-Ala tetrapeptide — small enough to cross plasma and nuclear membranes passively — can enter hepatocyte nuclei, interact with chromatin via sequence-selective contacts with histones and DNA, and preferentially activate transcription programmes that are normally suppressed by age and chronic stress. That model predicts selective reversal of age-related hepatic dysfunction without mitogenic or pro-inflammatory effects. The hypothesis is interesting and internally consistent within the Khavinson programme, but the molecular validation required by contemporary structural biology — co-crystal structures, ChIP-seq in hepatocyte models, chemically defined knock-out rescue — has not been published in Western-indexed literature. Readers should understand Livagen as an investigational Russian bioregulator with a sustained 25-year research programme inside one institute and minimal replication outside it. BodyHackGuide covers Livagen because it is frequently sold online — usually as 20 mg capsules containing roughly 2–4 mg of actual peptide per capsule — and because it appears in longevity-stack discussions alongside better-validated compounds. We describe what is known, what is claimed, and what is missing, and we steer readers who want evidence-graded hepatic support toward interventions with stronger replication: weight management, alcohol reduction, NAD+ precursors for mitochondrial support, Berberine and metformin for insulin-sensitising metabolic benefit in non-alcoholic fatty liver disease, and TUDCA (Tauroursodeoxycholic acid) for cholestatic biochemistry. Livagen is a plausible hypothesis. It is not, at this writing, an evidence-graded hepatic therapy.

Also known as: Thymalinum, Timalin, Thymus Peptide Complex, Thymic Extract, Khavinson Thymalin, T-activin (related), Thymalin-Vialing

Thymalin is a thymus-derived peptide complex developed in the 1970s by Vladimir Khavinson and the Leningrad (now St. Petersburg) Institute of Bioregulation and Gerontology as part of a broader program to identify tissue-specific regulatory peptides from mammalian organs. Produced by acetic acid extraction of bovine or calf thymus tissue and fractionated to yield a mixture of short polypeptides (average molecular weight 1-10 kDa), Thymalin occupies a distinctive position in peptide medicine: it is a registered pharmaceutical in Russia with over four decades of clinical use for immune restoration in aging and immunosuppressed populations, while remaining a research-chemical-status peptide in the United States and most Western markets where its evidence base is poorly integrated into mainstream medicine. Understanding Thymalin requires understanding the Russian peptide bioregulator tradition that produced it — a clinical and scientific framework quite different from Western pharmaceutical development, with its own standards of evidence, its own terminology, and its own strengths and limitations. Structurally, Thymalin is not a single molecule but a mixture of short polypeptides and oligopeptides derived from calf thymus gland. The specific peptide composition has been partially characterized in modern analytical work but never fully standardized in the way a single synthetic peptide would be. Active fractions include peptides with sequences overlapping Thymosin Alpha-1 and Thymulin, along with additional short regulatory peptides including the Khavinson lab's signature short synthetic peptides Epithalon (AEDG, from pineal) and related oligopeptides. The presumed active principle is a combination of these peptides acting synergistically on the immune system, though Khavinson's group has emphasized in their publications that the specific short peptides — which can be synthesized and studied individually — reproduce much of the biological activity of the whole extract. This is the foundation of the modern short-peptide Khavinson framework: Thymalin was the original mixture, and the individual dipeptides (like Livagen, Ala-Glu-Asp-Gly) and tetrapeptides (like Epithalon) identified from Thymalin and related extracts are the modern synthetic versions. Functionally, Thymalin is described by its developers as a "cytomedine" — a tissue-derived peptide regulator that carries organ-specific signals for cellular homeostasis and regeneration. The framework proposes that short peptides from specific tissues can enter cells (via membrane transport or endocytosis), travel to the nucleus, and interact with specific gene promoters to regulate transcription of tissue-specific genes. For Thymalin, this means carrying signals that promote thymic function, T-cell differentiation, and broader immune system homeostasis. The framework is provocative and not universally accepted in Western molecular biology — the specific proposition that exogenous short peptides can directly regulate gene transcription by binding promoters is considered unproven by most Western molecular biologists — but it has produced a coherent clinical research program with measurable outcomes in human trials. The clinical evidence base for Thymalin is substantial in volume and spans decades of use in Russian medicine. Khavinson and colleagues have published over two hundred papers on Thymalin and its derivatives, including multi-decade longitudinal trials in elderly populations showing reduced all-cause mortality, reduced incidence of acute respiratory infections, improvements in T-cell subset profiles (particularly CD4+ cells and the CD4:CD8 ratio), improved wound healing, and improvements in broader markers of immune competence and healthy aging. The most frequently cited data come from the "Kiev study" and subsequent Russian elderly cohort trials in which Thymalin (often in combination with Epithalon) administered in 10-day courses annually or biannually to elderly patients produced 2-fold reductions in cumulative 6-8 year mortality versus untreated controls. These are notable claims that would be transformative if replicated in a Western rigorous RCT framework — and the honest framing is that they have not been, not because replication has been attempted and failed, but because the Western peer-reviewed system has not seriously engaged with the Russian peptide bioregulator literature. This is an epistemic gap rather than a proven falsification, and it is the gap that every Western user of Thymalin should understand. Regulatory status varies dramatically by jurisdiction. In Russia, Thymalin is a registered pharmaceutical product (trade name Thymalin or Timalin) with Russian Ministry of Health approval for specific indications including post-infectious immune restoration, aging-related immunosuppression, radiation-induced immune compromise, and post-surgical immune support. It is prescribed routinely in Russian and some former Soviet clinical practice, particularly in geriatric medicine and oncology. In the United States, European Union, and most Western markets, Thymalin is not an approved pharmaceutical and is sold in the research-chemical peptide market — often imported directly from Russian manufacturers or compounded by specialty peptide suppliers. The research-chemical framing does not mean it is unsafe (its Russian safety record is substantial), but it means quality control is not regulated, pharmaceutical-grade standards are not guaranteed, and use is outside the framework of Western regulatory approval. The thymus biology context matters. The thymus is the organ where T-lymphocytes mature and are educated to distinguish self from non-self. Thymic function peaks in early childhood and then declines progressively through adulthood, a process called thymic involution — the thymus is largely replaced by fatty tissue by age 70 in most individuals, with corresponding decline in T-cell output and immune function. The elderly immune system is characterized by reduced naive T-cell pools, shrinking T-cell receptor diversity, expansion of senescent T-cell clones, and increased vulnerability to infections and cancer. The thymic-peptide hypothesis proposes that exogenous thymic signals can partially reverse or slow this involution and restore functional immune capacity. The biology is plausible; the clinical reality is harder to verify in Western-standards trials. In the research-peptide community outside Russia, Thymalin is used for immune support in contexts including aging, chronic infection recovery, post-chemotherapy immune restoration, chronic fatigue and post-viral syndromes, autoimmune disease management (controversial — thymic peptides might be immunomodulatory in either direction), and general longevity protocols. It is frequently combined with Epithalon (the Khavinson pineal tetrapeptide) as the canonical "Khavinson stack" reflecting the original clinical protocols. This entry covers Thymalin's composition and the cytomedine framework, the Khavinson clinical evidence base and its epistemic status, the distinction between Thymalin (mixture) and Thymosin Alpha-1 (single synthetic peptide, separate development track) and Thymulin (a zinc-dependent single peptide also distinct from Thymalin), the practical use case framing for Western research-peptide users, appropriate dosing based on Russian clinical protocols, the safety profile (substantial safety record in Russia, reasonably clean side-effect profile, but real questions about quality control in the Western research-chemical market), and honest skepticism about the grander anti-aging claims without dismissing the underlying immune-restoration evidence.